METHOD AND SYSTEM FOR PREDICTING CHILDHOOD OBESITY

Information

  • Patent Application
  • 20210038166
  • Publication Number
    20210038166
  • Date Filed
    August 05, 2020
    5 years ago
  • Date Published
    February 11, 2021
    4 years ago
Abstract
A method of predicting likelihood for childhood obesity, comprises: obtaining a plurality of parameters, wherein at least a few of the parameters characterize an infant or toddler subject. A machine learning procedure trained for predicting likelihoods for childhood obesity is feed with the plurality of parameters. An output indicative of a likelihood that the infant or toddler subject is expected to develop childhood obesity is received from the procedure. The output is related non-linearly to the parameters.
Description
FIELD AND BACKGROUND OF THE INVENTION

The present invention, in some embodiments thereof, relates to medicine and, more particularly, but not exclusively, to a method and system for predicting childhood obesity.


Over the past decades, the prevalence of childhood obesity has rapidly increased worldwide. A global analysis demonstrated that in 2016, 50 million girls and 74 million boys worldwide were obese, making it a global public health crisis. Obese children are very likely to have obesity persist into adulthood. Childhood obesity is associated with elevated blood pressure and lipids, and increased risk of diseases, such as asthma, type 2 diabetes, arthritis, and cardiovascular diseases at a later stage of life. Furthermore, childhood obesity can have a negative psycho-social effect.


Preventing excess weight gain in children is important for numerous reasons. Pediatric obesity is a multisystem disease that can greatly impact a child's physical and mental health. It is associated with a greater risk for premature mortality and earlier onset of chronic disorders such as hypertension, dyslipidemia, ischemic heart disease and type 2 diabetes, with insulin resistance identified in obese children as young as 5 years of age. Furthermore, there is currently an underestimation of obesity by parents and physicians and there is currently little guidance for health care professionals to identify infants at risk. Additionally, young age is a suitable time period for intervention, as it is associated with more beneficial long-term outcomes after lifestyle modifications.


SUMMARY OF THE INVENTION

According to an aspect of some embodiments of the present invention there is provided a method of predicting likelihood for childhood obesity. The method comprises: obtaining a plurality of parameters, wherein at least a few of the parameters characterize an infant or toddler subject; accessing a computer readable medium storing a machine learning procedure trained for predicting likelihoods for childhood obesity; feeding the procedure with the plurality of parameters; and receiving from the procedure an output indicative of a likelihood that the infant or toddler subject is expected to develop childhood obesity, wherein the output is related non-linearly to the parameters.


According to some embodiments of the invention the plurality of parameters comprises at least one parameter extracted from an electronic health record associated with the infant or toddler subject.


According to some embodiments of the invention the method comprises presenting to a user, by a user interface, a questionnaire and a set of questionnaire controls, receiving a set of response parameters entered by the user using the questionnaire controls, wherein the plurality of parameters comprises the response parameters.


According to some embodiments of the invention the plurality of parameters comprises at least one parameter extracted from a body liquid test applied to the infant or toddler subject.


According to some embodiments of the invention the plurality of parameters comprises at least one parameter characterizing a parent or a sibling of the infant or toddler subject.


According to some embodiments of the invention the at least one parameter characterizing the parent comprises a parameter extracted from a body liquid test applied to the parent or sibling.


According to some embodiments of the invention the plurality of parameters comprises at least one parameter extracted from a diagnosis previously recorded for the subject.


According to some embodiments of the invention the plurality of parameters comprises at least one parameter indicative of a pharmaceutical prescribed for the infant or toddler subject.


According to some embodiments of the invention the infant or toddler subject is less than two years of age.


According to some embodiments of the invention the infant or toddler subject is not obese. According to some embodiments of the invention the method wherein the infant or toddler subject has a normal weight. According to some embodiments of the invention the plurality of parameters comprises a weight-for-length score of the infant or toddler subject.


According to some embodiments of the invention the plurality of parameters comprise a weight of the infant or toddler subject at age of from about 4 to about 6 months, a weight of the infant or toddler subject at age of from about 12 to about 16 months, and a weight of the infant or toddler subject at age of from about 18 to about 22 months.


According to some embodiments of the invention the plurality of parameters comprises a parameter pertaining to a body-mass-index of a sibling of the infant or toddler subject.


According to some embodiments of the invention the plurality of parameters comprises a parameter pertaining to a body-mass-index of a father of the infant or toddler subject.


According to some embodiments of the invention the plurality of parameters comprises a result of a hemoglobin concentration test applied to the infant or toddler subject.


According to some embodiments of the invention the wherein the plurality of parameters comprises a result of a mean platelet volume test applied to the infant or toddler subject.


According to some embodiments of the invention the plurality of parameters comprises at least 10 or at least 20 or at least 30 or at least 40 or at least 50 or at least 100 or at least 200 or at least 300 or at least 400 or at least 500 or more of the parameters listed in Table 1.1.


According to some embodiments of the invention the plurality of parameters comprises at least 10 or at least 12 or at least 14 or at least 16 of the parameters that are listed at lines 1-40 more preferably lines 1-30 more preferably lines 1-20 of Table 1.1.


According to some embodiments of the invention the plurality of parameters comprises at least 20 or at least 22 or at least 24 or at least 26 or at least 28 or at least 30 or at least 32 or at least 34 or at least 36 of the parameters that are listed at lines 1-50 more preferably lines 1-45 more preferably lines 1-40 of Table 1.1.


According to some embodiments of the invention the plurality of parameters comprises least 50 or at least 60 or at least 70 or at least 80 or at least 90 of the parameters that are listed at lines 1-300 more preferably lines 1-200 more preferably lines 1-100 of


Table 1.1.


According to an aspect of some embodiments of the present invention there is provided a method of predicting likelihood for childhood obesity. The method comprises: obtaining a plurality of parameters characterizing at least one of a parent and a sibling of an unborn subject; accessing a computer readable medium storing a machine learning procedure trained for predicting likelihoods for childhood obesity; feeding the procedure with the plurality of parameters; and receiving from the procedure an output indicative of a likelihood that the unborn subject is expected to develop childhood obesity after birth, wherein the output is related non-linearly to the parameters.


According to some embodiments of the invention the plurality of parameters comprises at least one parameter extracted from an electronic health record associated with the at least one of the parent and the sibling.


According to some embodiments of the invention the method comprises presenting to a user, by a user interface, a questionnaire and a set of questionnaire controls, receiving a set of response parameters entered by the user using the questionnaire controls, wherein the plurality of parameters comprises the response parameters.


According to some embodiments of the invention the plurality of parameters comprises at least one parameter extracted from a body liquid test applied to the at least one of the parent and the sibling.


According to some embodiments of the invention the plurality of parameters comprises a parameter pertaining to a body-mass-index of the sibling.


According to some embodiments of the invention the plurality of parameters comprises a parameter pertaining to a body-mass-index of a father of the unborn subject.


According to some embodiments of the invention the plurality of parameters comprises at least 10 or at least 20 or at least 30 or at least 40 or at least 50 or at least 100 or at least 200 or at least 300 or at least 400 or at least 500 or at least 1,000 or at least 1,500 or more of the parameters listed in Table 1.2.


According to some embodiments of the invention the plurality of parameters comprises at least 10 or at least 12 or at least 14 or at least 16 of the parameters that are listed at lines 1-40 more preferably lines 1-30 more preferably lines 1-20 of Table 1.2.


According to some embodiments of the invention the plurality of parameters comprises at least 20 or at least 22 or at least 24 or at least 26 or at least 28 or at least 30 or at least 32 or at least 34 or at least 36 of the parameters that are listed at lines 1-50 more preferably lines 1-45 more preferably lines 1-40 of Table 1.2.


According to some embodiments of the invention the plurality of parameters comprises least 50 or at least 60 or at least 70 or at least 80 or at least 90 of the parameters that are listed at lines 1-300 more preferably lines 1-200 more preferably lines 1-100 of Table 1.2.


According to an aspect of some embodiments of the present invention there is provided a method of predicting likelihood for childhood obesity. The method comprises: presenting on a user interface a questionnaire and a set of questionnaire controls, and receiving from the user interface a set of response parameters entered using the questionnaire controls, wherein the set of response parameters characterizes an infant or toddler subject; accessing a computer readable medium storing a machine learning procedure trained for predicting likelihoods for childhood obesity; feeding the procedure with the set of parameters; and receiving from the procedure an output indicative of a likelihood that the infant or toddler subject is expected to develop childhood obesity, wherein the output is related non-linearly to the parameters.


According to some embodiments of the invention the plurality of parameters comprises at least 10 or at least 20 or at least 30 or at least 40 or at least 50 or more of the parameters listed in Table 1.3.


According to some embodiments of the invention the plurality of parameters comprises at least 10 or at least 12 or at least 14 or at least 16 of the parameters that are listed at lines 1-40 more preferably lines 1-30 more preferably lines 1-20 of Table 1.3.


According to some embodiments of the invention the plurality of parameters comprises at least 20 or at least 22 or at least 24 or at least 26 of the parameters that are listed at lines 1-50 more preferably lines 1-40 more preferably lines 1-30 of Table 1.3.


According to an aspect of some embodiments of the present invention there is provided a method of predicting likelihood for childhood obesity. The method comprises: presenting on a user interface a questionnaire and a set of questionnaire controls, and receiving from the user interface a set of response parameters entered using the questionnaire controls, wherein the set of response parameters characterizes at least one of a parent and a sibling of an unborn subject; accessing a computer readable medium storing a machine learning procedure trained for predicting likelihoods for childhood obesity; feeding the procedure with the set of parameters; and receiving from the procedure an output indicative of a likelihood that the unborn subject is expected to develop childhood obesity after birth, wherein the output is related non-linearly to the parameters.


According to some embodiments of the invention the plurality of parameters comprises at least 5 or at least 10 or at least 15 or more of the parameters listed in Table 1.4.


According to some embodiments of the invention the plurality of parameters comprises at least 5 or at least 10 of the parameters that are listed at lines 1-15 of Table 1.4.


Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.


Implementation of the method and/or system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of embodiments of the method and/or system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.


For example, hardware for performing selected tasks according to embodiments of the invention could be implemented as a chip or a circuit. As software, selected tasks according to embodiments of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In an exemplary embodiment of the invention, one or more tasks according to exemplary embodiments of method and/or system as described herein are performed by a data processor, such as a computing platform for executing a plurality of instructions. Optionally, the data processor includes a volatile memory for storing instructions and/or data and/or a non-volatile storage, for example, a magnetic hard-disk and/or removable media, for storing instructions and/or data. Optionally, a network connection is provided as well. A display and/or a user input device such as a keyboard or mouse are optionally provided as well.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.


In the drawings:



FIG. 1 is a flowchart diagram of a method suitable for predicting likelihood for childhood obesity, according to various exemplary embodiments of the present invention.



FIG. 2 is a schematic illustration of a client-server configuration which can be used according to some embodiments of the present invention for predicting likelihood for childhood obesity, according to some embodiments of the present invention.



FIG. 3 is a diagram illustrating a dataset of nationwide health records used in a study directed to a prediction of childhood obesity and an analysis of risk, according to some embodiments of the present invention.



FIGS. 4A-D show BMI dynamics in early childhood, as obtained in experiments performed according to some embodiments of the present invention. FIG. 4A shows mean BMI z-score for children who were obese (upper curve) versus non obese (lower curve) at 13 years of age. FIG. 4B shows mean change in annual BMI-scores for the same groups of children. Shaded areas are 95% bootstrapped confidence intervals. FIG. 4C shows obesity status transition of the study cohort. Left side: distribution of obesity status at the last available routine checkup before 2 years of age. Right side: distribution of obesity status at 5-6 years of age. Transitions from different obesity states between these two time points are presented. FIG. 4D shows distribution of obesity status at infancy for obese 5-6 years old children.



FIGS. 5A-D show evaluation of obesity prediction model constructed in accordance with some embodiments of the present invention. FIG. 5A shows ROC curve of the model of the present embodiments (solid line) and a baseline model based on the last available routine checkup measurement (dashed). The dots and percentages represent different decision probability thresholds. FIG. 5B is calibration curve. The dots represents deciles of predicted probabilities. The dotted diagonal line represents an ideal calibration. The histogram at the bottom represents predicted probabilities of normal-weight children and obese children. FIG. 5C shows a Precision-Recall curve. The Baseline model is marked with an X. Threshold percentiles are marked on the curves. FIG. 5D shows decision curve analysis containing different treatment strategies of the model according to some embodiments of the present invention (solid curve) and the baseline model (dashed curve). Strategies of treating all (dashed line), treating none (dotted line) and the perfect hypothetical predictor (dot-dash line) are also presented. Abbreviations: auPR/auROC—Area under the PR/ROC curve, PPV—positive predictive value, PR—Precision-Recall, ROC—Receiver-Operator-Characteristic



FIGS. 6A-C show discrimination performances of the obesity prediction model in accordance with some embodiments of the present invention. The discrimination performances are represented by Precision-Recall (auPR) according to last measured WFL percentile (FIG. 6A), different subpopulations of children (FIG. 6B), and the child's age (0-24 months) (FIG. 6C). Abbreviations: auPR—Area under the PR curve, PR—Precision-Recall, WFL—weight for length.



FIGS. 7A-H show interpretation of the model of the present embodiments. FIG. 7A shows Shapley values of different groups of features. FIGS. 7B-H are plots showing in the lower part a histogram of the distribution of a feature in the data and in the upper part a dependence plot of the predicted relative risk for obesity at 5-6 years of age versus the value of the feature for child last WFL z-score (FIG. 7B), child birth weight (FIG. 7C), siblings mean BMI z-score (FIG. 7D), maternal and paternal mean BMI (FIG. 7E); maternal 50 g GCT results during pregnancy (FIG. 7F), duration of antibiotic therapy calculated by the summation of the days in which the child was issued an antibiotics treatment (FIG. 7G), and Child North African Ethnicity index (FIG. 7H). Abbreviations: GCT—glucose challenge test, WFL—Weight-for-Length, y/o—years old.



FIGS. 8A and 8B show results of applying the childhood obesity prediction model of the present embodiments prior to 2 years of age. FIG. 8A shows auPR curve for prediction models of obesity at 5-6 years of age based on features that were extracted up to a predefined endpoint age, ranging from pre-birth to 2 years of age of note, auPR of the prediction model pre-birth and at birth overlap. The baseline model was defined as last routine checkup WFL z-score. FIG. 8B shows relative importance of groups of features for the prediction models, calculated by normalizing to the sum of mean absolute SHAP values for each model. “Others” sums up non-anthropometric or demographic features such as laboratory tests and drug features. Abbreviations: auPR—Area under the PR curve, PR—Precision-Recall, WFL—weight for length





DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

The present invention, in some embodiments thereof, relates to medicine and, more particularly, but not exclusively, to a method and system for predicting childhood obesity.


Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.



FIG. 1 is a flowchart diagram of a method suitable for predicting likelihood for childhood obesity, according to various exemplary embodiments of the present invention. It is to be understood that, unless otherwise defined, the operations described hereinbelow can be executed either contemporaneously or sequentially in many combinations or orders of execution. Specifically, the ordering of the flowchart diagrams is not to be considered as limiting. For example, two or more operations, appearing in the following description or in the flowchart diagrams in a particular order, can be executed in a different order (e.g., a reverse order) or substantially contemporaneously. Additionally, several operations described below are optional and may not be executed.


The processing operations of the present embodiments can be embodied in many forms. For example, they can be embodied in on a tangible medium such as a computer for performing the operations. They can be embodied on a computer readable medium, comprising computer readable instructions for carrying out the method operations. They can also be embodied in electronic device having digital computer capabilities arranged to run the computer program on the tangible medium or execute the instruction on a computer readable medium.


Computer programs implementing the method according to some embodiments of this invention can commonly be distributed to users on a distribution medium such as, but not limited to, CD-ROM, flash memory devices, flash drives, or, in some embodiments, drives accessible by means of network communication, over the internet (e.g., within a cloud environment), or over a cellular network. From the distribution medium, the computer programs can be copied to a hard disk or a similar intermediate storage medium. The computer programs can be run by loading the computer instructions either from their distribution medium or their intermediate storage medium into the execution memory of the computer, configuring the computer to act in accordance with the method of this invention. Computer programs implementing the method according to some embodiments of this invention can also be executed by one or more data processors that belong to a cloud computing environment. All these operations are well-known to those skilled in the art of computer systems. Data used and/or provided by the method of the present embodiments can be transmitted by means of network communication, over the internet, over a cellular network or over any type of network, suitable for data transmission.


The method according to preferred embodiments of the present invention can be embedded into healthcare systems and may allow identification and implementation of prevention strategies for children at high risk for obesity.


The method begins at 10 and continues to 11 at which a plurality of parameters characterizing is obtained. The inventors discovered that the likelihood for childhood obesity can be predicted both for infant or toddler subjects and for unborn subjects, e.g., during the pregnancy of a female carrying the unborn subject.


As used herein “infant” refers to an individual not more that 1 year of age, and “toddler” refers to an individual above 1 year of age and not more than 3 years of age”


Thus, in some embodiments of the present invention the method predicts likelihood that an infant or toddler subject is expected to develop childhood obesity, and in some embodiments of the present invention the method predicts unborn subject is expected to develop childhood obesity after birth. When the subject is an infant or toddler subject he or she is preferably of less than two years of age. The method of the present embodiments is typically used for estimating the likelihood that the subject is expected to develop childhood obesity at age greater than the toddler age, e.g., more than 4 years of age, for example, from about 5 to about 6 years of age.


When the subject is an infant or toddler subject, at least one of the parameters that are obtained at 11, more preferably more than one of these parameters, more preferably at least 10 or at least 20 or at least 30 or at least 40 or at least 50 or at least 100 or at least 200 or at least 300 or at least 400 or at least 500 or more of the parameters are extracted from an electronic health record associated with the subject. Parameters extracted from an electronic health record can include, but are not limited to, anthropometric parameters (e.g., height, weight, body mass index, weight-for-length score), blood pressure measurements, blood and urine laboratory tests, diagnoses recorded by physicians, and/or pharmaceuticals prescribed to the subject.


In some embodiments of the present invention at least one of the parameters that are obtained at 11, more preferably more than one of these parameters, more preferably at least 10 or at least 20 or at least 30 or at least 40 or at least 50 or at least 100 or at least 200 or at least 300 or at least 400 or at least 500 or more of the parameters are extracted from an electronic health record associated with a parent (mother and/or father) and/or a sibling (brother and or sister) of the subject. These parameters can include any of the aforementioned parameters associated with the subject, except that they describe the respective parent or sibling (e.g., anthropometric parameters, blood pressure measurements, blood and urine laboratory tests, diagnoses, pharmaceuticals).


When the subject is an unborn subject, there are typically no parameters that describe the subject itself, and so the parameters that are obtained at 11 are typically associated with a parent (mother and/or father) and/or a sibling (brother and or sister) of the subject, as further detailed hereinabove.


A list of parameters from which the parameters can be selected when the subject is an infant or toddler subject is provided in Table 1.1 of the Examples section that follows, and list of parameters from which the parameters can be selected when the subject is an unborn subject is provided in Table 1.2 of the Examples section that follows. In some embodiments of the present invention at least 10 or at least 20 or at least 30 or at least 40 or at least 50 or at least 100 or at least 200 or at least 300 or at least 400 or at least 500 are selected from the parameters listed in Table 1.1 (for an infant or toddler subject) or Table 1.2 (for an unborn subject). Preferably, but not necessarily, at least 10 or at least 12 or at least 14 or at least 16 of the parameters are selected from the parameters that are listed at lines 1-40 more preferably lines 1-30 more preferably lines 1-20 of Table 1.1 (for an infant or toddler subject) or Table 1.2 (for an unborn subject). In some embodiments, at least 20 or at least 22 or at least 24 or at least 26 or at least 28 or at least 30 or at least 32 or at least 34 or at least 36 of the parameters are selected from the parameters that are listed at lines 1-50 more preferably lines 1-45 more preferably lines 1-40 of Table 1.1 (for an infant or toddler subject) or Table 1.2 (for an unborn subject). In some embodiments, at least 50 or at least 60 or at least 70 or at least 80 or at least 90 of the parameters are selected from the parameters that are listed at lines 1-300 more preferably lines 1-200 more preferably lines 1-100 of Table 1.1 (for an infant or toddler subject) or Table 1.2 (for an unborn subject).


Also contemplated are embodiments in which the parameters are selected from a set of response parameters that are provided by a person on behalf of the subject (e.g., a parent, a sibling, etc.), by responding to a questionnaire presented to the person. These parameters can include anthropometric parameters (e.g., height, weight, body mass index, weight-for-length score), one or more parameters indicative of the age of the subject (if born), and one or more parameters indicative of the ethnicity of the subject. A list of parameters which can be provided by responding to the questionnaire is provided in Table 1.3 for the case in which the subject is an infant or toddler subject, and in Table 1.4 for the case in which the subject is an unborn subject.


In some embodiments of the present invention the parameters include only parameters extracted from one or more electronic health records, in some embodiments of the present invention the parameters include only response parameters that are provided on behalf of the subject, and in some embodiments of the present invention the parameters include both parameters extracted from electronic health record(s) and response parameters that are provided by the subject or on her behalf.


In some embodiments of the present invention the electronic health record(s) include a record that is associated with the subject, in some embodiments of the present invention parameters the electronic health record(s) include records that are associated with at least one of a parent and a sibling of the subject, and in some embodiments of the present invention the electronic health record(s) include at least one record that is associated with the subject, and at least one record that is associated with a parent and/or a sibling of the subject.


The number of parameters that are extracted from the electronic health record(s) associated is preferably at least 10 or at least 20 or at least 30 or at least 40 or at least 50 or at least 100 or at least 200 or at least 300 or at least 400 or at least 500 or more. The number of response parameters that are provided by the subject or on her behalf is preferably 100 or less, or 80 or less, or 70 or less. The advantage of this embodiment is that a relative small number of parameter allows the subject to manually respond to the questionnaire at a relatively short time.


When the parameters include both parameters extracted from electronic health record(s), and response parameters that are provided on behalf of the subject, the number of parameters that are extracted from the electronic health record(s) is optionally and preferably significantly larger (e.g., at least 2 or at least 3 or at least 4 or at least 5 or at least 6 or at least 7 or at least 8 or at least 9 or at least 10 times larger) than the number of response parameters that are provided on behalf of the subject.


In some embodiments of the present invention at least one of the parameters is extracted from a body liquid test applied to the infant or toddler subject. Representative examples of body liquid tests from which a parameter can extracted from a body liquid test applied to the infant or toddler subject according to some embodiments of the present invention include, without limitation, Albumin test, Alk. phosphatase test, Atypical lymph. %-dif test, Atypical lymph-dif test, Basophils percentage (Baso %) test, Basophils (Baso abs) test, Bilirubin total test, Bilirubin-direct test, Calcium test, Chloride test, Cholesterol test, C-reactive protein test, Creatinine test, Eos % test, Eos.abs test, Eosinophils abs-dif test, Eosinophils %-dif test, Ferritin test, Gamma glutamyl transferase (Ggt) test, Glucose test, Got (ast) test, Alanine aminotransferase (Gpt (alt)) test, hemoglobin concentration (Hb) test, Hematocrit (Hct) test, Hematocrit/hemoglobin (Hct/hgb) ratio test, Hyper % test, Hypochromic red cells (Hypo %) test, Iron test, Ldh test, Luc abs test, Luc % test, Lym % test, Lymp.abs test, Lymphocytes %-dif test, Lymphocytes abs-dif test, Macro % test, Mean cell hemoglobin (Mch) test, mean hemoglobin concentration (Mchc) test, mean corpuscular volume (Mcv) test, Micro % test, Micro %/hypo % test, Mono % test, Mono.abs test, Monocytes abs-dif test, Monocytes %-dif test, mean platelet volume (Mpv) test, Mpxi test, Neut % test, Neut.abs test, Neutrophils abs-dif test, Neutrophils %-dif test, Pct test, Pdw test, Phosphorus test, platelet count blood (Plt) test, Potassium test, Protein-total test, Rbc test, red cell distribution width (Rdw) test, Red blood cell distribution width presented as the coefficient of variation (Rdw-cv) test, Sodium test, Stabs %-dif test, Stabs abs-dif test, T4-free test, Transferrin test, Triglycerides test, Thyroid-stimulating hormone (Tsh) test, Urea test, Uric acid test, and white blood cells (Wbc) test.


In some embodiments of the present invention at least one of the parameters is extracted from a body liquid test applied to the mother of the infant or toddler subject during pregnancy of the mother with the infant or toddler subject. Representative examples of body liquid tests from which a parameter can extracted from a body liquid test applied to the mother according to some embodiments of the present invention include, without limitation, Albumin, Alk. phosphatase, Alpha fetoprotein tm, Amylase, Aptt-r, Aptt-sec, Baso %, Baso abs, Bilirubin indirect, Bilirubin total, Bilirubin-direct, Blood type, Calcium, Chloride, Cholesterol-hdl, Cholesterol, Cholesterol/hdl, Cholesterol-ldl calc, Ck-creat.kinase(cpk), Cmv igg, Control ptt, Creatinine, Dhea sulphate, Eos %, Eos.abs, Eosinophils abs-dif, Eosinophils %-dif, Esr, Estradiol (e-2), Ferritin, Fibrinogen calcu, Fibrinogen, Folic acid, Fsh, Ggt, Globulin, Glom.filtr.rate, Glucose (gtt) 0′, Glucose (gtt) 120′, Glucose (gtt) 180′, Glucose (gtt) 60′, Glucose 50 g, Glucose, Got (ast), Gpt (alt), Hb, Hba, Hba2, Hbf, Hct, Hct/hgb ratio, Hdw, Hemoglobin a, Hemoglobin alc %, Hepatitis bs ab, Hyper %, Hypo %, Iron, Ldh, Lh, Li, Luc abs, Luc %, Lym %, Lymp.abs, Lymphocytes %-dif, Lymphocytes abs-dif, Macro %, Magnesium, Mch, Mchc, Mcv, Micro %, Micro %/hypo %, Mono %, Mono.abs, Monocytes abs-dif, Monocytes %-dif, Mpv, Mpxi, Neut %, Neut.abs, Neutrophils abs-dif, Neutrophils %-dif, Non-hdl_cholesterol, Normoblast. %, Normoblast.abs, Pct, Pdw, Phosphorus, Plt, Potassium, Progesterone, Prolactin, Protein-total, Pt %, Pt-inr, Pt-sec, Rbc, Rdw, Rdw-cv, Rubella ab igg, Sodium, Stabs %-dif, Stabs abs-dif, T3-free, T4-free, Toxoplasma igg, Transferrin, Triglycerides, Tsh, Urea, Uric acid, Vitamin b12, Vitamin d (25-oh), and Wbc.


In some embodiments of the present invention at least one of the parameters is extracted from a test applied to the mother of the infant or toddler subject prior to the pregnancy of the mother with the infant or toddler subject. Representative examples such tests include, without limitation, 17-oh-progesterone, Albumin, Alk. phosphatase, Aly, Aly %, Amylase, Androstenedione, Anti cardiolipin igg, Anti cardiolipin igm, Antithrombin-iii, Aptt-r, Aptt-sec, Baso %, Baso abs, Bilirubin indirect, Bilirubin total, Bilirubin-direct, Blood type, BMI, Ca-125, Calcium, Chloride, Cholesterol-hdl, Cholesterol, Cholesterol/hdl, Cholesterol-ldl calc, Ck-creat.kinase(cpk), Cmv igg, Complement c3, Complement c4, Control ptt, Cortisol-blood, C-reactive protein, Creatinine, Dhea sulphate, Eos %, Eos.abs, Eosinophils %-dif, Esr, Estradiol (e-2), Ferritin, Fibrinogen calcu, Fibrinogen, Folic acid, Free androgen index, Fsh, Ggt, Globulin, Glom.filtr.rate, Glucose 50 g, Glucose, Got (ast), Gpt (alt), Hb, Hba2, Hbf, Hct, Hct/hgb ratio, Hdw, Hemoglobin a, Hemoglobin alc %, Hepatitis bs ab, Hyper %, Hypo %, Iga, Iron, Ldh, Lh, Lic, Lic %, Luc abs, Luc %, Lym %, Lymp.abs, Lymphocytes %-dif, Lymphocytes abs-dif, Macro %, Magnesium, Mch, Mchc, Mcv, Micro %, Micro %/hypo %, Mono %, Mono.abs, Monocytes abs-dif, Monocytes %-dif, Mpv, Mpxi, Neut %, Neut.abs, Neutrophils abs-dif, Neutrophils %-dif, Non-hdl_cholesterol, Normoblast. %, Normoblast.abs, Pct, Pdw, Phosphorus, Plt, Potassium, Progesterone, Prolactin, Protein c activity, Protein-total, Prot-s antigen (free, Pt %, Pt-inr, Pt-sec, Rbc, Rdw, Rdw-cv, Rubella ab igg, Shbg, Sodium, T3-free, T3-total, T4-free, Testosterone-total, Toxoplasma igg, Transferrin, Triglycerides, Tsh, Urea, Uric acid, Vitamin b12, Vitamin d (25-oh), Vldl, Wbc, and Weight.


In some embodiments of the present invention the plurality of parameters comprises a result of a blood glucose test applied to the mother of the subject.


In some embodiments of the present invention at least one of the parameters is extracted from a test applied to the father of the infant or toddler subject. Representative examples of such tests include, without limitation, Age at the birth of the subject, BMI count, BMI max, BMI mean, BMI median, BMI min, BMI standard deviation (std), Height count, Height max, Height mean, Height median, Height min, Height std, max Cholesterol-hdl, max Cholesterol, max Cholesterol/hdl, max Cholesterol-ldl calc, max Glucose, max Non-hdl_cholesterol, max Triglycerides, mean Cholesterol-hdl, mean Cholesterol, mean Cholesterol/hdl, mean Cholesterol-ldl calc, mean Glucose, mean Non-hdl_cholesterol, mean Triglycerides, median Cholesterol-hdl, median Cholesterol, median Cholesterol/hdl, median Cholesterol-ldl calc, median Glucose, median Non-hdl_cholesterol, median Triglycerides, min Cholesterol-hdl, min Cholesterol, min Cholesterol/hdl, min Cholesterol-ldl calc, min Glucose, min Non-hdl_cholesterol, min Triglycerides, std Cholesterol-hdl, std Cholesterol, std Cholesterol/hdl, std Cholesterol-ldl calc, std Glucose, std Non-hdl_cholesterol, std Triglycerides, Weight count, Weight max, Weight mean, Weight median, Weight min, and Weight std.


In some embodiments of the present invention one or more of the parameters is a result of a hemoglobin concentration test (Hb) applied to the subject.


In some embodiments of the present invention one or more of the parameters is a result of a mean platelet volume test (Mpv) applied to the subject.


In some embodiments of the present invention one or more of the parameters is a result of a Basophils percentage test (Baso %) applied to the subject.


In some embodiments of the present invention one or more of the parameters is a result of a red cell distribution width test (Rdw) applied to the subject.


In some embodiments of the present invention one or more of the parameters is a result of a platelet count blood test (plt) applied to the subject.


In some embodiments of the present invention the parameters comprise at least one parameter extracted from a clinical or hospital diagnosis previously recorded for the subject. Representative examples of clinical and hospital diagnoses which can be used as parameters according to some embodiments of the present invention include, without limitation, Abdominal pain, Abnormal loss of weight, Abnormal weight gain, Accident/injury; nos, Acquired deformities of other parts of limbs, Acute and unspecified inflammation of lacrimal passages, Acute bronchiolitis, Acute bronchitis, Acute conjunctivitis, Acute laryngitis, Acute laryngotracheitis, Acute lymphadenitis, Acute myringitis without mention of otitis media, Acute nasopharyngitis (common cold), Acute nonsuppurative otitis media, Acute pharyngitis, Acute suppurative otitis media, Acute tonsillitis, Acute upper respiratory infections of multiple or unsp.sites, Acute upper respiratory infections of unspecified site, Agranulocytosis, Allergic rhinitis, Allergy, unspecified, not elsewhere classified, Allergy/allergic react nos, Anal fissure, Anemia other/unspecified, Anorexia, Asthma, Asthma, unspecified, Atopic dermatitis/eczema, Benign neoplasm of skin, site unspecified, Blepharitis, Blisters with epidermal loss,burn 2nd.deg.unspecified site, Bronchopneumonia, organism unspecified, Candidiasis of mouth, Candidiasis of skin and nails, Candidiasis of unspecified site, Cellulitis and abscess of finger, Cellulitis and abscess of unspecified sites, Chronic rhinitis, Chronic serous otitis media, Colitis, enteritis, gastroenteritis presumed infectious origin, Congenital anomalies of lower limb, including pelvic girdle, Congenital dislocation of hip, Congenital musculoskeletal deformities of sternocleidomastoid, Constipation, Contact dermatitis and other eczema, Contact dermatitis and other eczema, unspecified cause, Contusion of unspecified site, Convulsions, Cough, Croup, Delivery in a completely normal case, Dermatitis due to food taken internally, Dermatophytosis of the body, Diaper or napkin rash, Diarrhea, Diseases and other conditions of the tongue, Disorders relating to other preterm infants, Dyspnea and respiratory abnormalities, Enlargement of lymph nodes, Enteritis due to specified virus, Enterobiasis, Esophagitis, Feeding difficulties and mismanagement, Fever, Gastrointestinal hemorrhage, Hand, foot, and mouth disease, Hearing complaints, Hearing loss, Hemangioma of unspecified site, Herpangina, Hip symptoms/complaints, Hydrocele, Hydronephrosis, Hypermetropia, Hypertrophy of tonsils and adenoids, Impetigo, Infectious colitis, enteritis, and gastroenteritis, Infectious diarrhea, Infectious mononucleosis, Infective otitis externa, Influenza, Inguinal hernia, without mention of obstruction or gangrene, Injuries, Insect bite, Insect bite, nonvenomous face, neck, scalp without infection, Intestinal malabsorption, Iron deficiency anemia, unspecified, Irritable infant, Jaundice, unspecified, not of newborn, Laceration/cut, Lack of coordination, Lack of expected normal physiological development, Late effect of injury to cranial nerve, Laxity of ligament, Nausea and vomiting, Nervousness, Nonsuppurative otitis media, not specified as acute or chronic, Open wound of face, without mention of complication, Oral aphthae, Otalgia, Other and unspec.noninfectious gastroenteritis and colitis, Other and unspecified chronic nonsuppurative otitis media, Other and unspecified injury to unspecified site, Other atopic dermatitis and related conditions, Other diseases of conjunctiva due to viruses and chlamydiae, Other diseases of nasal cavity and sinuses, Other serum reaction, not elsewhere classified, Other specified disease of white blood cells, Other specified erythematous conditions, Other specified viral exanthemata, Other speech disturbance, Other symptoms involving digestive system, Other viral diseases; nos, Otorrhea, Pneumonia, Pneumonia, organism unspecified, Posttraumatic wound infection not elsewhere classified, Premat/immature liveborn infant, Rash and other nonspecific skin eruption, Seborrhea, Seborrheic dermatitis, unspecified, Serous otitis media;glue, Sleep disturbances, Sneezing/nasal congestion, Stenosis and insufficiency of lacrimal passages, Stomatitis, Strabismus and other disorders of binocular eye movements, Stridor, Teething syndrome, Tongue tie, Torticollis, unspecified, U.r.i. (head cold), Umbilical hernia without mention of obstruction or gangrene, Undescended testicle, Unsp.adv.effect of drug,medicinal/biological substance n.e.s., Unsp.viral infect.in conditions classif.elsewhere, unsp.site, Unspecified fetal and neonatal jaundice, Unspecified otitis media, Urinary tract infection, site not specified, Urticaria, Varicella without mention of complication, Viral exanthem, unspecified, Viral pneumonia, Volume depletion disorder, Vomiting (excl.preg. w06), and Wheezing baby syndrome.


In some embodiments of the present invention the parameters comprise at least one parameter indicative of a pharmaceutical prescribed for the subject. Representative examples of prescribed pharmaceuticals which can be used as parameters according to some embodiments of the present invention include, without limitation, Aciclovir, Ahiston drop cd, Amoxicillin, Azithromycin, Bethamethasone, Budesonide, Cefaclor, Cefalexin, Ceftriaxone, Cefuroxime, Co-amoxiclav cd, Co-trimoxazole cd, Desloratadine, Dimethindene, Erythromycin, Fluticasone, Ipratropium bromide, Ketotifen, Loratadine, Mebendazole, Metronidazole, Montelukast, Phenoxymethylpenicillin, Prednisolone, Prothiazine/promethazine expectorant cd, Ranitidine, Salbutamol, and Terbutaline.


In some embodiments of the present invention the parameters comprise at least one parameter indicative of a count of Salbutamol prescriptions provided for the infant or toddler subject.


In some embodiments of the present invention the parameters comprise at least one parameter indicative of a count of Bethamethasone prescriptions provided for the infant or toddler subject.


In some embodiments of the present invention the parameters comprise at least one parameter indicative of a count of Budesonide prescriptions provided for the infant or toddler subject.


In some embodiments of the present invention the parameters comprise at least one parameter indicative of a pharmaceutical prescribed for the mother of the subject. Representative examples of prescribed pharmaceuticals which can be used as parameters according to some embodiments of the present invention include, without limitation, Aciclovir, Amoxicillin, Anti-d (rh) immunoglobulin, Aspirin, Bethamethasone, Budesonide, Cabergoline, Carbamazepine, Cefalexin, Cefuroxime, Cetirizine, Choriogonadotropin alfa, Chorionic gonadotrophin, Ciprofloxacin, Citalopram, Clarithromycin, Clomifene, Clonazepam, Co-amoxiclav cd, Colchicine, Desloratadine, Desogestrel and ethinylestradiol, Desogestrel, Dexamethasone, Doxycycline, Drospirenone and ethinylestradiol, Dydrogesterone, Enoxaparin, Escitalopram, Estradiol, Famotidine, Fexofenadine, Fluconazole, Fluoxetine, Fluticasone, Follitropin alfa, Follitropin beta, Gestodene and ethinylestradiol, Human menopausal gonadotrophin, Ipratropium bromide, Lamotrigine, Lansoprazole, Levothyroxine sodium, Loratadine, Mebendazole, Medroxyprogesterone, Methylphenidate, Metronidazole, Nitrofurantoin, Norethisterone, Norgestimate and ethinylestradiol, Ofloxacin, Omeprazole, Paroxetine, Phenoxymethylpenicillin, Prednisone, Progesterone, Progyluton cd, Roxithromycin, Salbutamol, Seretide cd, Sertraline, Simvastatin, Symbicort/duoresp, and Triptorelin.


In some embodiments of the present invention the parameters comprise at least one parameter indicative of a pharmaceutical prescribed for the father of the subject. Representative examples of prescribed pharmaceuticals which can be used as parameters according to some embodiments of the present invention include, without limitation, Amlodipine, Atenolol, Atorvastatin, Bezafibrate, Bisoprolol, Cholesterol-hdl, Cholesterol, Cholesterol/hdl, Cholesterol-ldl calc, Enalapril, Glucose, Insulin glargine, Metformin and sitagliptin cd, Metformin, Nifedipine, Nifedipine-cd, Non-hdl_cholesterol, Pravastatin, Propranolol, Ramipril, Ramipril-hydrochlorothiazide cd, Rosuvastatin, Simvastatin, and Triglycerides.


In some embodiments of the present invention the parameters comprise at least one parameter extracted from a clinical or hospital diagnosis previously recorded for the father of subject. Representative examples of clinical and hospital diagnoses which can be used as parameters according to some embodiments of the present invention include, without limitation, Diabetes mellitus, unspecified Obesity, Obesity (BMI>30), other and unspecified hyperlipidemia, Essential hypertension, Morbid obesity, unspecified essential hypertension, Overweight (BMI<30), other abnormal glucose, Lipid metabolism disorder, Impaired fasting glucose, Disorders of lipoid metabolism, Diabetes mellitus without mention of complication, and Adult-onset type diabetes mellitus without complication.


Referring again to FIG. 1, the method proceeds to 12 at which a computer readable medium storing a machine learning procedure is accessed. The machine learning procedure is trained for predicting likelihoods for childhood obesity.


As used herein the term “machine learning” refers to a procedure embodied as a computer program configured to induce patterns, regularities, or rules from previously collected data to develop an appropriate response to future data, or describe the data in some meaningful way.


Representative examples of machine learning procedures suitable for the present embodiments, include, without limitation, clustering, association rule algorithms, feature evaluation algorithms, subset selection algorithms, support vector machines, classification rules, cost-sensitive classifiers, vote algorithms, stacking algorithms, Bayesian networks, decision trees, neural networks, instance-based algorithms, linear modeling algorithms, k-nearest neighbors (KNN) analysis, ensemble learning algorithms, probabilistic models, graphical models, logistic regression methods (including multinomial logistic regression methods), gradient ascent methods, singular value decomposition methods and principle component analysis.


Following is an overview of some machine learning procedures suitable for the present embodiments.


Support vector machines are algorithms that are based on statistical learning theory. A support vector machine (SVM) according to some embodiments of the present invention can be used for classification purposes and/or for numeric prediction. A support vector machine for classification is referred to herein as “support vector classifier,” support vector machine for numeric prediction is referred to herein as “support vector regression”.


An SVM is typically characterized by a kernel function, the selection of which determines whether the resulting SVM provides classification, regression or other functions. Through application of the kernel function, the SVM maps input vectors into high dimensional feature space, in which a decision hyper-surface (also known as a separator) can be constructed to provide classification, regression or other decision functions. In the simplest case, the surface is a hyper-plane (also known as linear separator), but more complex separators are also contemplated and can be applied using kernel functions. The data points that define the hyper-surface are referred to as support vectors.


The support vector classifier selects a separator where the distance of the separator from the closest data points is as large as possible, thereby separating feature vector points associated with objects in a given class from feature vector points associated with objects outside the class. For support vector regression, a high-dimensional tube with a radius of acceptable error is constructed which minimizes the error of the data set while also maximizing the flatness of the associated curve or function. In other words, the tube is an envelope around the fit curve, defined by a collection of data points nearest the curve or surface.


An advantage of a support vector machine is that once the support vectors have been identified, the remaining observations can be removed from the calculations, thus greatly reducing the computational complexity of the problem. An SVM typically operates in two phases: a training phase and a testing phase. During the training phase, a set of support vectors is generated for use in executing the decision rule. During the testing phase, decisions are made using the decision rule. A support vector algorithm is a method for training an SVM. By execution of the algorithm, a training set of parameters is generated, including the support vectors that characterize the SVM. A representative example of a support vector algorithm suitable for the present embodiments includes, without limitation, sequential minimal optimization.


In KNN analysis, the affinity or closeness of objects is determined. The affinity is also known as distance in a feature space between objects. Based on the determined distances, the objects are clustered and an outlier is detected. Thus, the KNN analysis is a technique to find distance-based outliers based on the distance of an object from its kth-nearest neighbors in the feature space. Specifically, each object is ranked on the basis of its distance to its kth-nearest neighbors. The farthest away object is declared the outlier. In some cases the farthest objects are declared outliers. That is, an object is an outlier with respect to parameters, such as, a k number of neighbors and a specified distance, if no more than k objects are at the specified distance or less from the object. The KNN analysis is a classification technique that uses supervised learning. An item is presented and compared to a training set with two or more classes. The item is assigned to the class that is most common amongst its k-nearest neighbors. That is, compute the distance to all the items in the training set to find the k nearest, and extract the majority class from the k and assign to item.


Association rule algorithm is a technique for extracting meaningful association patterns among features.


The term “association”, in the context of machine learning, refers to any interrelation among features, not just ones that predict a particular class or numeric value. Association includes, but it is not limited to, finding association rules, finding patterns, performing feature evaluation, performing feature subset selection, developing predictive models, and understanding interactions between features.


The term “association rules” refers to elements that co-occur frequently within the datasets. It includes, but is not limited to association patterns, discriminative patterns, frequent patterns, closed patterns, and colossal patterns.


A usual primary step of association rule algorithm is to find a set of items or features that are most frequent among all the observations. Once the list is obtained, rules can be extracted from them.


The aforementioned self-organizing map is an unsupervised learning technique often used for visualization and analysis of high-dimensional data. Typical applications are focused on the visualization of the central dependencies within the data on the map. The map generated by the algorithm can be used to speed up the identification of association rules by other algorithms. The algorithm typically includes a grid of processing units, referred to as “neurons”. Each neuron is associated with a feature vector referred to as observation. The map attempts to represent all the available observations with optimal accuracy using a restricted set of models. At the same time the models become ordered on the grid so that similar models are close to each other and dissimilar models far from each other. This procedure enables the identification as well as the visualization of dependencies or associations between the features in the data.


Feature evaluation algorithms are directed to the ranking of features or to the ranking followed by the selection of features based on their impact.


Information gain is one of the machine learning methods suitable for feature evaluation. The definition of information gain requires the definition of entropy, which is a measure of impurity in a collection of training instances. The reduction in entropy of the target feature that occurs by knowing the values of a certain feature is called information gain. Information gain may be used as a parameter to determine the effectiveness of a feature in explaining the response to the treatment. Symmetrical uncertainty is an algorithm that can be used by a feature selection algorithm, according to some embodiments of the present invention. Symmetrical uncertainty compensates for information gain's bias towards features with more values by normalizing features to a [0,1] range.


Subset selection algorithms rely on a combination of an evaluation algorithm and a search algorithm. Similarly to feature evaluation algorithms, subset selection algorithms rank subsets of features. Unlike feature evaluation algorithms, however, a subset selection algorithm suitable for the present embodiments aims at selecting the subset of features with the highest impact on predicting likelihood for childhood obesity, while accounting for the degree of redundancy between the features included in the subset. The benefits from feature subset selection include facilitating data visualization and understanding, reducing measurement and storage requirements, reducing training and utilization times, and eliminating distracting features to improve classification.


Two basic approaches to subset selection algorithms are the process of adding features to a working subset (forward selection) and deleting from the current subset of features (backward elimination). In machine learning, forward selection is done differently than the statistical procedure with the same name. The feature to be added to the current subset in machine learning is found by evaluating the performance of the current subset augmented by one new feature using cross-validation. In forward selection, subsets are built up by adding each remaining feature in turn to the current subset while evaluating the expected performance of each new subset using cross-validation. The feature that leads to the best performance when added to the current subset is retained and the process continues. The search ends when none of the remaining available features improves the predictive ability of the current subset. This process finds a local optimum set of features.


Backward elimination is implemented in a similar fashion. With backward elimination, the search ends when further reduction in the feature set does not improve the predictive ability of the subset. The present embodiments contemplate search algorithms that search forward, backward or in both directions. Representative examples of search algorithms suitable for the present embodiments include, without limitation, exhaustive search, greedy hill-climbing, random perturbations of subsets, wrapper algorithms, probabilistic race search, schemata search, rank race search, and Bayesian classifier.


A decision tree is a decision support algorithm that forms a logical pathway of steps involved in considering the input to make a decision.


The term “decision tree” refers to any type of tree-based learning algorithms, including, but not limited to, model trees, classification trees, and regression trees.


A decision tree can be used to classify the datasets or their relation hierarchically. The decision tree has tree structure that includes branch nodes and leaf nodes. Each branch node specifies an attribute (splitting attribute) and a test (splitting test) to be carried out on the value of the splitting attribute, and branches out to other nodes for all possible outcomes of the splitting test. The branch node that is the root of the decision tree is called the root node. Each leaf node can represent a classification (e.g., whether a particular parameter influences on the likelihood for childhood obesity) or a value (e.g., the predicted likelihood for childhood obesity). The leaf nodes can also contain additional information about the represented classification such as a confidence score that measures a confidence level in the represented classification (i.e., the accuracy of the prediction).


Regression techniques which may be used in accordance with some embodiments the present invention include, but are not limited to linear Regression, Multiple Regression, logistic regression, probit regression, ordinal logistic regression ordinal Probit-Regression, Poisson Regression, negative binomial Regression, multinomial logistic Regression (MLR) and truncated regression.


A logistic regression or logit regression is a type of regression analysis used for predicting the outcome of a categorical dependent variable (a dependent variable that can take on a limited number of values, whose magnitudes are not meaningful but whose ordering of magnitudes may or may not be meaningful) based on one or more predictor variables. Logistic regression may also predict the probability of occurrence for each data point. Logistic regressions also include a multinomial variant. The multinomial logistic regression model is a regression model which generalizes logistic regression by allowing more than two discrete outcomes. That is, it is a model that is used to predict the probabilities of the different possible outcomes of a categorically distributed dependent variable, given a set of independent variables (which may be real-valued, binary-valued, categorical-valued, etc.). For binary-valued variables, a cutoff between the 0 and 1 associations is typically determined using the Yuden Index.


A Bayesian network is a model that represents variables and conditional interdependencies between variables. In a Bayesian network variables are represented as nodes, and nodes may be connected to one another by one or more links. A link indicates a relationship between two nodes. Nodes typically have corresponding conditional probability tables that are used to determine the probability of a state of a node given the state of other nodes to which the node is connected. In some embodiments, a Bayes optimal classifier algorithm is employed to apply the maximum a posteriori hypothesis to a new record in order to predict the probability of its classification, as well as to calculate the probabilities from each of the other hypotheses obtained from a training set and to use these probabilities as weighting factors for future predictions of the likelihood for childhood obesity. An algorithm suitable for a search for the best Bayesian network, includes, without limitation, global score metric-based algorithm. In an alternative approach to building the network, Markov blanket can be employed. The Markov blanket isolates a node from being affected by any node outside its boundary, which is composed of the node's parents, its children, and the parents of its children.


Instance-based techniques generate a new model for each instance, instead of basing predictions on trees or networks generated (once) from a training set.


The term “instance”, in the context of machine learning, refers to an example from a dataset.


Instance-based techniques typically store the entire dataset in memory and build a model from a set of records similar to those being tested. This similarity can be evaluated, for example, through nearest-neighbor or locally weighted methods, e.g., using Euclidian distances. Once a set of records is selected, the final model may be built using several different techniques, such as the naive Bayes.


Neural networks are a class of algorithms based on a concept of inter-connected “neurons.” In a typical neural network, neurons contain data values, each of which affects the value of a connected neuron according to connections with predefined strengths, and whether the sum of connections to each particular neuron meets a predefined threshold. By determining proper connection strengths and threshold values (a process also referred to as training), a neural network can achieve efficient recognition of images and characters. Oftentimes, these neurons are grouped into layers in order to make connections between groups more obvious and to each computation of values. Each layer of the network may have differing numbers of neurons, and these may or may not be related to particular qualities of the input data.


In one implementation, called a fully-connected neural network, each of the neurons in a particular layer is connected to and provides input value to those in the next layer. These input values are then summed and this sum compared to a bias, or threshold. If the value exceeds the threshold for a particular neuron, that neuron then holds a positive value which can be used as input to neurons in the next layer of neurons. This computation continues through the various layers of the neural network, until it reaches a final layer. At this point, the output of the neural network routine can be read from the values in the final layer. Unlike fully-connected neural networks, convolutional neural networks operate by associating an array of values with each neuron, rather than a single value. The transformation of a neuron value for the subsequent layer is generalized from multiplication to convolution.


The machine learning procedure used according to some embodiments of the present invention is a trained machine learning procedure, which provides output that is related non-linearly to the parameters with which it is fed.


A machine learning procedure can be trained according to some embodiments of the present invention by feeding a machine learning training program with parameters that characterizes each of a cohort of subjects that has been diagnosed as either having or not having childhood obesity at obesity at age greater than the toddler age. Once the data are fed, the machine learning training program generates a trained machine learning procedure which can then be used without the need to re-train it.


For example, when it is desired to employ decision trees, machine learning training program learns the structure of each tree in a plurality of decision trees (e.g., how many nodes there are in each tree, and how these are connected to one another), and also selects the decision rules for split nodes of each tree. At least a portion of the decision rules relate to one or more of the parameters that characterize the subject. A simple decision rule may be a threshold for the value of a particular parameter, but more complex rules, relating to more than one parameter are also contemplated. The machine learning training program also accumulates data at the leaves of the trees. The structures of the trees, the decision rules for the split nodes, and the data at the leaves are all selected by the machine learning training program, automatically and typically without user intervention, such that the parameters at the root of the trees provide the likelihood for childhood obesity at the leaves of the trees. The final result of the machine learning training program in this case is a set of trees, where the structures, the decision rules for split nodes, and leaf data for each trees are defined by the machine learning training program.


The method proceeds to 13 at which the trained machine learning procedure is fed with the parameters, and to 14 at which an output indicative of the likelihood that the subject is expected to develop childhood obesity is received from the procedure. Preferably, the procedure provides the likelihood that the subject is expected to develop childhood obesity at an age greater than the toddler are, as further detailed hereinabove. In some embodiments of the present invention the method proceeds to 15 at which a report predating to the likelihood is generated. The report can be displayed on a display device or transmitted to a computer readable medium.


The method ends at 16.


The prediction of likelihood for childhood obesity can be executed according to some embodiments of the present invention by a server-client configuration, as will now be explained with reference to FIG. 2.



FIG. 2 illustrates a client computer 30 having a hardware processor 32, which typically comprises an input/output (I/O) circuit 34, a hardware central processing unit (CPU) 36 (e.g., a hardware microprocessor), and a hardware memory 38 which typically includes both volatile memory and non-volatile memory. CPU 36 is in communication with I/O circuit 34 and memory 38. Client computer 30 preferably comprises a user interface, e.g., a graphical user interface (GUI), 42 in communication with processor 32. I/O circuit 34 preferably communicates information in appropriately structured form to and from GUI 42. Also shown is a server computer 50 which can similarly include a hardware processor 52, an I/O circuit 54, a hardware CPU 56, a hardware memory 58. I/O circuits 34 and 54 of client 30 and server 50 computers preferable operate as transceivers that communicate information with each other via a wired or wireless communication. For example, client 30 and server 50 computers can communicate via a network 40, such as a local area network (LAN), a wide area network (WAN) or the Internet. Server computer 50 can be in some embodiments be a part of a cloud computing resource of a cloud computing facility in communication with client computer 30 over the network 40.


GUI 42 and processor 32 can be integrated together within the same housing or they can be separate units communicating with each other. GUI 42 can optionally and preferably be part of a system including a dedicated CPU and I/O circuits (not shown) to allow GUI 42 to communicate with processor 32. Processor 32 issues to GUI 42 graphical and textual output generated by CPU 36. Processor 32 also receives from GUI 42 signals pertaining to control commands generated by GUI 42 in response to user input. GUI 42 can be of any type known in the art, such as, but not limited to, a keyboard and a display, a touch screen, and the like. In preferred embodiments, GUI 42 is a GUI of a mobile device such as a smartphone, a tablet, a smartwatch and the like. When GUI 42 is a GUI of a mobile device, the CPU circuit of the mobile device can serve as processor 32 and can execute the method optionally and preferably by executing code instructions.


Client 30 and server 50 computers can further comprise one or more computer-readable storage media 44, 64, respectively. Media 44 and 64 are preferably non-transitory storage media storing computer code instructions for executing the method of the present embodiments, and processors 32 and 52 execute these code instructions. The code instructions can be run by loading the respective code instructions into the respective execution memories 38 and 58 of the respective processors 32 and 52. Storage media 64 preferably also store one or more databases including a database of psychologically annotated olfactory perception signatures as further detailed hereinabove.


In operation, processor 32 of client computer 30 displays on GUI 42 a questionnaire and a set of questionnaire controls, such as, but not limited to, a slider, a dropdown menu, a combo box, a text box and the like. A representative example of a displayed questionnaire 60 and a set of controls 62 is shown in FIG. 6C. A person on behalf of the subject can enter response parameters using the questionnaire controls displayed on GUI 42.


Processor 32 receives the response parameters from GUI 42 and typically transmits these parameters to server computer 50 over network 40. Media 64 can store a machine learning procedure trained for predicting likelihoods for childhood obesity. Server computer 50 can access media 64, feed the stored procedure with the parameters received from client computer 30, and receive from the procedure an output indicative of the likelihood that the subject that is characterized by the parameters is expected to develop childhood obesity. Server computer 50 can also transmit to client computer 30 the obtained likelihood, and client computer 30 can display this information on GUI 42.


As used herein the term “about” refers to ±10%.


The word “exemplary” is used herein to mean “serving as an example, instance or illustration.” Any embodiment described as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments and/or to exclude the incorporation of features from other embodiments.


The word “optionally” is used herein to mean “is provided in some embodiments and not provided in other embodiments.” Any particular embodiment of the invention may include a plurality of “optional” features unless such features conflict.


The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.


The term “consisting of” means “including and limited to”.


The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.


As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.


Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.


Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.


As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.


As used herein, the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.


It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.


Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.


EXAMPLES

Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.


Example 1

Table 1.1 presents a list of 945 parameters from which parameters for feeing the machine learning procedure can be selected when the subject is an infant or toddler subject. The list is sorted according the significance of the respective feature for predicting the likelihood for childhood obesity, in descending order, so that from the standpoint of prediction accuracy it is more preferred to select a parameter that is listed higher in Table 1.1, than a parameter that is listed lower in Table 1.1. For example, when N parameters are used, it is preferred to select those parameters from lines 1 through M of Table 1.1, where N≤M≤945.










TABLE 1.1





No.
Parameter
















1
Last WFL zscore


2
Weight Routine checkup - 18-22 months


3
Weight Routine checkup - 12-16 months


4
WFL zscore median


5
Siblings median BMI zscore mean


6
WFL zscore mean


7
Weight Routine checkup - 4-6 months


8
Ethnicity: North Africa


9
Siblings mean BMI zscore mean


10
Siblings max BMI zscore mean


11
Father BMI median


12
WFL Routine checkup - 18-22 months


13
WFL zscore max


14
Father BMI max


15
Child mean Hb


16
Siblings at 5 years of age BMI zscore mean


17
Siblings min BMI zscore mean


18
Father BMI mean


19
Child mean Mpv


20
Father BMI min


21
Mother Pre-Pregnancy BMI max


22
Child All Antibiotics prescription day counts


23
Weight Routine checkup - 9-12 months


24
Mother Pre-Pregnancy BMI median


25
Child diagnosed Acute upper respiratory infections of multiple or



unsp.sites


26
Mother 24-40 weeks MCV


27
Height Routine checkup - 12-16 months


28
Mother Pre-Pregnancy BMI mean


29
Child mean Baso %


30
Mother 24-40 weeks MCH


31
Child mean Rdw


32
Child mean Plt


33
Child count Salbutamol


34
Height Routine checkup - 18-22 months


35
Weight Routine checkup - 6-9 months


36
Age of Father at birth


37
Child mean Eosinophils abs-dif


38
Siblings count BMI zscore std


39
Mother Pre-Pregnancy BMI min


40
WFL Routine checkup - 1-2 months


41
Ethnicity: Ethiopia


42
Weight Routine checkup - 2-3 months


43
Child mean Mcv


44
Child count Bethamethasone


45
Mother last BMI 24-40 weeks


46
Age of Mother at birth


47
WFL Routine checkup - 9-12 months


48
WFL zscore slope


49
Father Weight median


50
WFL Routine checkup - 12-16 months


51
Locality type: Jewish Locality 100,000-199,999 residents


52
Age at last WFL


53
Mother Pre-Pregnancy Weight max


54
Ethnicity: Unknown


55
Weight Routine checkup - 1-2 months


56
Mother last BMI 0-12 weeks


57
WFL zscore intercept


58
Height Routine checkup - 4-6 months


59
Child diagnosed Nausea and vomiting


60
Ethnicity: North America


61
Father Height median


62
Height Routine checkup - 6-9 months


63
Mother Pre-Pregnancy Weight mean


64
Ethnicity: West Europe


65
Child mean Hct


66
Locality type: Non-Jewish Locality 5,000-9,999 residents


67
Child mean Ggt


68
Mother 12-24 weeks VITAMIN B12


69
Child diagnosed Dyspnea and respiratory abnormalities


70
Mother 0-12 weeks MCH


71
Child mean Mch


72
Father std Cholesterol


73
Child mean Wbc


74
Child diagnosed Colitis, enteritis, gastroenteritis presumed



infectious origin


75
Child diagnosed Acute upper respiratory infections of unspecified



site


76
Mother Pre-Pregnancy Weight median


77
Siblings min BMI zscore std


78
Child mean Protein-total


79
Week of year born


80
Child mean Hypo %


81
Mother Pre-Pregnancy Weight min


82
WFL zscore min


83
Child diagnosed Hypertrophy of tonsils and adenoids


84
Mother Pre-pregnancy CMV IgG


85
Mother Pre-pregnancy PDW


86
Child diagnosed Acute tonsillitis


87
Mother 24-40 weeks GLUCOSE 50 g


88
Mother Pre-pregnancy GGT


89
Child mean Gpt (alt)


90
Child mean Albumin


91
Child diagnosed Fever


92
Child mean Ferritin


93
Father Height mean


94
Height Routine checkup - 9-12 months


95
Ethnicity: Iraq


96
Siblings mean BMI zscore std


97
Child count Budesonide


98
Father max Triglycerides


99
Mother 12-24 weeks RBC


100
Mother 0-12 weeks WBC


101
Siblings std BMI zscore mean


102
Mother last Diastolic Blood Pressure 24-40 weeks


103
Mother 12-24 weeks HB


104
Mother 12-24 weeks LUC %


105
Child Penicillin Antibiotics prescription day counts


106
Child mean Ldh


107
Mother 0-12 weeks VITAMIN B12


108
Child diagnosed Lack of coordination


109
Mother 0-12 weeks HCT


110
Mother Pre-pregnancy GLUCOSE 50 g


111
Father mean Cholesterol- hdl


112
Father mean Triglycerides


113
Father Height min


114
Child mean Tsh


115
Siblings count BMI zscore mean


116
Mother 0-12 weeks LYMP.abs


117
Child mean Rdw-cv


118
WFL Routine checkup - 6-9 months


119
Locality type: Non-Jewish Locality 10,000-19,999 residents


120
Mother Pre-pregnancy GLUCOSE


121
Child diagnosed Acute bronchiolitis


122
Mother last BMI 12-24 weeks


123
Father std Glucose


124
Mother Pre-pregnancy CK—CREAT.KINASE(CPK)


125
Child mean Creatinine


126
Father std Cholesterol-ldl calc


127
Father min Cholesterol- hdl


128
Mother last BMI Pre-pregnancy


129
Mother Pre-pregnancy TSH


130
Date of Birth


131
Mother last Weight Pre-pregnancy


132
Mother Pre-pregnancy MCHC


133
Mother Pre-pregnancy LYMP.abs


134
Siblings median BMI zscore std


135
Mother 12-24 weeks IRON


136
Mother count Roxithromycin


137
Mother last Weight 12-24 weeks


138
Mother 24-40 weeks MPV


139
Mother 12-24 weeks GLUCOSE


140
Mother Pre-pregnancy PT %


141
Height Routine checkup - 2-3 months


142
Mother 24-40 weeks VITAMIN B12


143
Father max Glucose


144
Father Weight max


145
Mother 24-40 weeks EOS %


146
Child diagnosed Cough


147
Child count Amoxicillin


148
Mother 24-40 weeks GLUCOSE (GTT) 0′


149
Mother Pre-pregnancy HCT


150
Mother Pre-pregnancy BILIRUBIN-DIRECT


151
Age at Target measurement


152
Mother 0-12 weeks MPV


153
Ethnicity: East Europe


154
Siblings max BMI zscore std


155
Child mean Glucose


156
Child mean Stabs %-dif


157
Height Routine checkup - 1-2 months


158
Father mean Glucose


159
Child mean Mono %


160
Mother 0-12 weeks NEUT.abs


161
Child mean Neutrophils abs-dif


162
Father Weight mean


163
Mother Pre-pregnancy T4- FREE


164
WFL zscore slope_std_err


165
Mother 24-40 weeks RBC


166
Mother Pre-pregnancy LYM %


167
Child diagnosed Hearing loss


168
Child mean Eos.abs


169
Child mean Sodium


170
Mother 24-40 weeks ALK. PHOSPHATASE


171
Child diagnosed Urinary tract infection, site not specified


172
Child mean Luc abs


173
Mother 0-12 weeks EOS.abs


174
Father min Triglycerides


175
Mother 0-12 weeks MONO.abs


176
Child mean Luc %


177
Mother Pre-pregnancy MPV


178
Mother Pre-pregnancy NEUT %


179
Mother 24-40 weeks APTT-R


180
Child diagnosed Otorrhea


181
Siblings at 13 years of age BMI zscore mean


182
Ethnicity: Muslim Arab


183
Child mean Atypical lymph.%-dif


184
Mother Pre-pregnancy PHOSPHORUS


185
WFL Routine checkup - 2-3 months


186
Father count Metformin


187
WFL zscore count


188
Child mean T4- free


189
Mother Pre-pregnancy NEUT.abs


190
Mother 12-24 weeks MCHC


191
Child mean Chloride


192
Mother 24-40 weeks HEMOGLOBIN A1C %


193
Mother Pre-pregnancy CHOLESTEROL-LDL calc


194
Child mean Lym %


195
Child mean Mono.abs


196
Child diagnosed Sleep disturbances


197
Child mean Micro %


198
Child mean Calcium


199
Child mean Rbc


200
Mother last Systolic Blood Pressure 0-12 weeks


201
Child mean Lymphocytes abs-dif


202
WFL Routine checkup - 4-6 months


203
Father median Triglycerides


204
Mother 24-40 weeks MICRO %


205
Mother last Systolic Blood Pressure 12-24 weeks


206
Mother 24-40 weeks MONO.abs


207
Mother 12-24 weeks PLT


208
Locality type: Jewish Locality 10,000-19,999 residents


209
Child mean Alk. phosphatase


210
Child mean Baso abs


211
Child mean Eos %


212
Mother Pre-pregnancy LDH


213
Child mean Atypical lymph-dif


214
Mother 0-12 weeks HEPATITIS Bs Ab


215
Child mean Hyper %


216
Child mean Got (ast)


217
Mother Pre-pregnancy PLT


218
Father min Glucose


219
Child mean Lymp.abs


220
Father max Non-hdl_cholesterol


221
Mother 12-24 weeks NEUT %


222
Mother 24-40 weeks HYPO %


223
Mother last Systolic Blood Pressure Pre-pregnancy


224
Father Height max


225
Mother last Systolic Blood Pressure 24-40 weeks


226
Father median Cholesterol- hdl


227
Mother 12-24 weeks T4- FREE


228
Mother Pre-pregnancy UREA


229
Mother Pre-pregnancy MAGNESIUM


230
Mother 0-12 weeks CHOLESTEROL/HDL


231
Child mean Mchc


232
Mother 24-40 weeks LYM %


233
Mother 12-24 weeks MCV


234
Mother Pre-pregnancy MONO.abs


235
Child mean Neut.abs


236
Mother Pre-pregnancy WBC


237
Mother 12-24 weeks MONO.abs


238
Mother 24-40 weeks HCT


239
Mother 0-12 weeks CMV IgG


240
Mother 24-40 weeks PLT


241
WFL zscore std


242
Birth weight


243
Mother Pre-pregnancy PROTEIN-TOTAL


244
Mother 12-24 weeks CMV IgG


245
Child mean Cholesterol


246
Mother 24-40 weeks CMV IgG


247
Mother 0-12 weeks SODIUM


248
Mother 24-40 weeks NEUT %


249
Mother 24-40 weeks MCHC


250
Father Weight min


251
Mother count Amoxicillin


252
Father mean Cholesterol


253
Child mean Bilirubin total


254
Father median Glucose


255
Child mean Pdw


256
Mother Pre-pregnancy CHOLESTEROL


257
Child Macrolides Antibiotics prescription day counts


258
Mother 0-12 weeks MONO %


259
Mother 24-40 weeks LYMP.abs


260
Mother 12-24 weeks NEUT.abs


261
Mother Pre-pregnancy HYPER %


262
Child mean Iron


263
Mother 12-24 weeks TSH


264
Mother count Cabergoline


265
Mother last Weight 0-12 weeks


266
Mother Pre-pregnancy PCT


267
Father Height std


268
Mother 0-12 weeks TRIGLYCERIDES


269
Mother 0-12 weeks GLUCOSE


270
Father std Cholesterol/hdl


271
Mother Pre-pregnancy HYPO %


272
Mother 24-40 weeks FERRITIN


273
Child count Terbutaline


274
Child mean Monocytes %-dif


275
Jewish Locality


276
Child mean Uric acid


277
Child diagnosed Acute nonsuppurative otitis media


278
Father BMI std


279
Mother Pre-pregnancy BASO %


280
Mother 24-40 weeks SODIUM


281
Mother Pre-pregnancy VITAMIN B12


282
Mother 0-12 weeks ESTRADIOL (E-2)


283
Mother 0-12 weeks LYM %


284
Mother 12-24 weeks EOS %


285
Mother 24-40 weeks NEUT.abs


286
Mother 24-40 weeks NEUTROPHILS abs-DIF


287
Father diagnosed Diabetes mellitus


288
Mother Pre-pregnancy CREATININE


289
Child Cephalosporin Antibiotics prescription day counts


290
Father Weight std


291
Mother 24-40 weeks HB


292
Mother BMI delta 12-24 weeks to 24-40 weeks


293
Mother 0-12 weeks GGT


294
Child mean Urea


295
Mother 0-12 weeks LH


296
Mother 24-40 weeks RDW


297
Mother 12-24 weeks HbA2


298
Mother 0-12 weeks MCV


299
Mother Pre-pregnancy MONO %


300
Mother Pre-pregnancy HB


301
Child mean Micro %/hypo %


302
Mother 24-40 weeks LUC %


303
Mother count Enoxaparin


304
Child mean Monocytes abs-dif


305
Mother 24-40 weeks MONO %


306
Mother 0-12 weeks NEUT %


307
Mother 24-40 weeks WBC


308
Child diagnosed Acute conjunctivitis


309
Father mean Non-hdl_cholesterol


310
Child mean Neutrophils %-dif


311
Mother 0-12 weeks EOS %


312
Mother 0-12 weeks RDW


313
Mother Pre-pregnancy RDW


314
Mother 12-24 weeks LYM %


315
Mother Pre-pregnancy SHBG


316
Mother Pre-pregnancy FOLIC ACID


317
Child mean Transferrin


318
Child diagnosed Other viral diseases; nos


319
Mother 0-12 weeks HYPO %


320
Mother Pre-pregnancy MICRO %


321
Mother 24-40 weeks BILIRUBIN TOTAL


322
Child mean Lymphocytes %-dif


323
Mother Pre-pregnancy SODIUM


324
Mother Pre-pregnancy RBC


325
Child diagnosed Teething syndrome


326
Child count Prednisolone


327
Mother 24-40 weeks BASO %


328
Mother 24-40 weeks LYMPHOCYTES abs-DIF


329
Mother 0-12 weeks PROGESTERONE


330
Father BMI count


331
Mother Pre-pregnancy TRIGLYCERIDES


332
Father max Cholesterol


333
Mother 12-24 weeks LYMP.abs


334
Child diagnosed Benign neoplasm of skin, site unspecified


335
Mother last Diastolic Blood Pressure 0-12 weeks


336
Mother Pre-pregnancy GLOBULIN


337
Mother 24-40 weeks CREATININE


338
Father max Cholesterol-ldl calc


339
Father max Cholesterol- hdl


340
Mother Pre-pregnancy ESR


341
Mother 12-24 weeks PT-SEC


342
Mother 24-40 weeks LUC abs


343
Mother 24-40 weeks MPXI


344
Mother Pre-Pregnancy BMI std


345
Mother 12-24 weeks FERRITIN


346
Mother 0-12 weeks MPXI


347
Mother 0-12 weeks TSH


348
Mother 24-40 weeks GOT (AST)


349
Mother 24-40 weeks HYPER %


350
Mother 24-40 weeks EOSINOPHILS abs-DIF


351
Mother 12-24 weeks WBC


352
Father mean Cholesterol-ldl calc


353
Ethnicity: Iran


354
Child count Dimethindene


355
Father std Triglycerides


356
Mother Pre-pregnancy HDW


357
Mother 0-12 weeks UREA


358
Mother 12-24 weeks HCT


359
Mother Pre-pregnancy HEPATITIS Bs Ab


360
Child mean Triglycerides


361
Child diagnosed Acute lymphadenitis


362
Mother 0-12 weeks LDH


363
Mother 12-24 weeks POTASSIUM


364
Child mean Neut %


365
Child diagnosed Unspecified fetal and neonatal jaundice


366
Mother Pre-Pregnancy Weight std


367
Mother 12-24 weeks MICRO %


368
Mother Pre-pregnancy BILIRUBIN TOTAL


369
Mother 0-12 weeks HB


370
Child mean Mpxi


371
Mother Pre-pregnancy C-REACTIVE PROTEIN


372
Mother Pre-pregnancy MCV


373
Mother Pre-pregnancy DHEA SULPHATE


374
Child mean Pct


375
Father min Cholesterol


376
Locality type: Jewish Locality 50,000-99,999 residents


377
Mother Pre-pregnancy EOS %


378
Father median Cholesterol


379
Child mean Hct/hgb ratio


380
Mother 24-40 weeks BILIRUBIN-DIRECT


381
Child diagnosed Diaper or napkin rash


382
Mother 24-40 weeks STABS %-DIF


383
Child mean Stabs abs-dif


384
Siblings at 5 years of age BMI zscore std


385
Child diagnosed Congenital anomalies of lower limb, including



pelvic girdle


386
Father std Cholesterol- hdl


387
Child count Cefalexin


388
Mother 12-24 weeks HYPO %


389
Child diagnosed Oral aphthae


390
Mother 24-40 weeks STABS abs-DIF


391
Child mean Phosphorus


392
Mother 0-12 weeks LUC %


393
Mother 12-24 weeks SODIUM


394
Mother 24-40 weeks GLUCOSE (GTT) 60′


395
Mother 24-40 weeks CHOLESTEROL


396
Child count Erythromycin


397
No. of Siblings with BMI data


398
Mother 12-24 weeks CREATININE


399
Mother 24-40 weeks GLUCOSE (GTT) 180′


400
Mother 12-24 weeks EOS.abs


401
Child diagnosed Asthma


402
Mother Pre-pregnancy COMPLEMENT C3


403
Mother Pre-pregnancy EOS.abs


404
Ethnicity: Asian


405
Mother 24-40 weeks T3- FREE


406
Mother Pre-pregnancy FERRITIN


407
Mother Pre-pregnancy AMYLASE


408
Father count Pravastatin


409
Mother 24-40 weeks MONOCYTES abs-DIF


410
Mother 24-40 weeks GPT (ALT)


411
Mother Pre-pregnancy URIC ACID


412
Father diagnosed Obesity, unspecified


413
Mother 24-40 weeks NEUTROPHILS %-DIF


414
Child diagnosed Bronchopneumonia, organism unspecified


415
Mother 0-12 weeks MCHC


416
Mother 12-24 weeks MONO %


417
Mother Pre-pregnancy FIBRINOGEN CALCU


418
Mother Pre-pregnancy MPXI


419
Child Beta lactam Penicillin Antibiotics prescription day counts


420
Mother 0-12 weeks URIC ACID


421
Mother Pre-pregnancy LH


422
Mother 24-40 weeks MACRO %


423
Mother Pre-pregnancy MCH


424
Mother 24-40 weeks BASO abs


425
Father count Cholesterol-ldl calc


426
Mother 0-12 weeks MICRO %


427
Mother Weight delta Pre-pregnancy to 0-12 weeks


428
Child diagnosed Constipation


429
Siblings std BMI zscore std


430
Mother 24-40 weeks LDH


431
Mother 0-12 weeks PLT


432
Siblings at 13 years of age BMI zscore std


433
Father count Glucose


434
Mother Pre-pregnancy BILIRUBIN INDIRECT


435
Child mean Eosinophils %-dif


436
Mother 24-40 weeks URIC ACID


437
Mother BMI delta Pre-pregnancy to 0-12 weeks


438
Mother 12-24 weeks GGT


439
Mother 0-12 weeks GPT (ALT)


440
Mother 0-12 weeks PHOSPHORUS


441
Mother Pre-pregnancy LUC %


442
Child diagnosed U.r.i. (head cold)


443
Mother 0-12 weeks HYPER %


444
Mother 0-12 weeks CREATININE


445
Mother 12-24 weeks MICRO %/HYPO %


446
Mother 0-12 weeks MACRO %


447
Mother 12-24 weeks RDW


448
Mother Pre-pregnancy POTASSIUM


449
Mother 0-12 weeks RBC


450
Mother Pre-pregnancy ALK. PHOSPHATASE


451
Child diagnosed Enlargement of lymph nodes


452
Mother Pre-pregnancy ALBUMIN


453
Mother 12-24 weeks TRIGLYCERIDES


454
Mother 0-12 weeks AMYLASE


455
Father min Cholesterol-ldl calc


456
Mother 0-12 weeks ALK. PHOSPHATASE


457
Mother Pre-pregnancy PT-SEC


458
Child diagnosed Diarrhea


459
Mother 0-12 weeks VITAMIN D (25-OH)


460
Child diagnosed Pneumonia


461
Mother 12-24 weeks MCH


462
Child mean Potassium


463
Mother Pre-pregnancy CALCIUM


464
Father count Cholesterol- hdl


465
Father median Cholesterol-ldl calc


466
Mother Pre-pregnancy COMPLEMENT C4


467
Mother count Ofloxacin


468
Child mean C-reactive protein


469
Mother last Weight 24-40 weeks


470
Mother 0-12 weeks CHOLESTEROL-LDL calc


471
Mother Pre-pregnancy MACRO %


472
Mother count Phenoxymethylpenicillin


473
Mother 0-12 weeks HDW


474
Mother 24-40 weeks TRIGLYCERIDES


475
Mother Pre-pregnancy TESTOSTERONE- TOTAL


476
Father std Non-hdl_cholesterol


477
Child diagnosed Contusion of unspecified site


478
Mother 0-12 weeks NON-HDL_CHOLESTEROL


479
Child diagnosed Esophagitis


480
Child mean Macro %


481
Mother last Diastolic Blood Pressure Pre-pregnancy


482
Mother 0-12 weeks APTT-sec


483
Child count Cefuroxime


484
Child diagnosed Atopic dermatitis/eczema


485
Mother 24-40 weeks MICRO %/HYPO %


486
Ethnicity: USSR


487
Mother 12-24 weeks MPXI


488
Mother 0-12 weeks BASO %


489
Father min Non-hdl_cholesterol


490
Mother Pre-pregnancy NON-HDL_CHOLESTEROL


491
Mother 0-12 weeks GLOBULIN


492
Mother 12-24 weeks MACRO %


493
Child diagnosed Stridor


494
Father count Simvastatin


495
Mother 12-24 weeks LUC abs


496
Child diagnosed Infectious diarrhea


497
Mother 12-24 weeks PT-INR


498
Mother 0-12 weeks GOT (AST)


499
Father min Cholesterol/hdl


500
Mother 24-40 weeks GLUCOSE


501
Mother 24-40 weeks EOS.abs


502
Child diagnosed Chronic rhinitis


503
Mother 12-24 weeks UREA


504
Mother 0-12 weeks PROTEIN-TOTAL


505
Mother Pre-pregnancy ALY


506
Mother Pre-pregnancy FREE ANDROGEN INDEX


507
Child diagnosed Unsp.viral infect.in conditions classif.elsewhere,



unsp.site


508
Mother 0-12 weeks POTASSIUM


509
Mother 12-24 weeks AMYLASE


510
Mother 12-24 weeks CK—CREAT.KINASE(CPK)


511
Mother Pre-pregnancy GPT (ALT)


512
Mother 0-12 weeks CHOLESTEROL


513
Mother 12-24 weeks BASO %


514
Child diagnosed Anorexia


515
Mother Pre-pregnancy CORTISOL-BLOOD


516
Mother 24-40 weeks RDW-CV


517
Mother Pre-pregnancy ESTRADIOL (E-2)


518
Mother 12-24 weeks MPV


519
Child diagnosed Other specified disease of white blood cells


520
Mother Pre-pregnancy PROLACTIN


521
Mother 24-40 weeks TSH


522
is Male


523
Child diagnosed Lack of expected normal physiological



development


524
Mother 0-12 weeks CK—CREAT.KINASE(CPK)


525
Father median Non-hdl_cholesterol


526
Father mean Cholesterol/hdl


527
Mother 0-12 weeks FOLIC ACID


528
Mother 24-40 weeks IRON


529
Mother 0-12 weeks LUC abs


530
Mother Pre-pregnancy RUBELLA Ab IgG


531
Mother 0-12 weeks ALBUMIN


532
Child mean Bilirubin-direct


533
Mother 0-12 weeks IRON


534
Mother 0-12 weeks RUBELLA Ab IgG


535
Mother 24-40 weeks AMYLASE


536
Number of twin siblings


537
Mother Pre-pregnancy ANDROSTENEDIONE


538
Father count Enalapril


539
Mother count Mebendazole


540
Mother 24-40 weeks CHLORIDE


541
Child diagnosed Influenza


542
Child count Desloratadine


543
Mother 24-40 weeks HDW


544
Child count Ketotifen


545
Child diagnosed Dermatitis due to food taken internally


546
Mother 24-40 weeks GLUCOSE (GTT) 120′


547
Father count Cholesterol


548
Mother 12-24 weeks PCT


549
Mother 24-40 weeks UREA


550
Child count Ipratropium bromide


551
Child diagnosed Acute pharyngitis


552
Child diagnosed Acute suppurative otitis media


553
Mother 0-12 weeks TOXOPLASMA IgG


554
Mother Pre-pregnancy MICRO %/HYPO %


555
Mother 24-40 weeks PROTEIN-TOTAL


556
Mother 12-24 weeks TOXOPLASMA IgG


557
Mother 0-12 weeks FSH


558
Father count Non-hdl_cholesterol


559
Child diagnosed Acute nasopharyngitis (common cold)


560
Mother 24-40 weeks CHOLESTEROL- HDL


561
Mother 24-40 weeks PT-SEC


562
Mother Pre-pregnancy ANTI CARDIOLIPIN IgG


563
Mother Pre-Pregnancy BMI count


564
Mother 24-40 weeks PDW


565
Mother 24-40 weeks MONOCYTES %-DIF


566
Mother 0-12 weeks MICRO %/HYPO %


567
Mother Pre-pregnancy TRANSFERRIN


568
Mother Pre-pregnancy GOT (AST)


569
Child diagnosed Other diseases of conjunctiva due to viruses and



chlamydiae


570
Mother Pre-pregnancy PT-INR


571
Mother 24-40 weeks CALCIUM


572
Child diagnosed Other atopic dermatitis and related conditions


573
Mother 0-12 weeks HEMOGLOBIN A


574
Mother Pre-pregnancy LUC abs


575
Father count Amlodipine


576
Mother 12-24 weeks ALK. PHOSPHATASE


577
Father count Triglycerides


578
Mother 0-12 weeks CALCIUM


579
Child count Azithromycin


580
Mother 12-24 weeks FOLIC ACID


581
Mother Pre-pregnancy FSH


582
Child diagnosed Pneumonia, organism unspecified


583
Mother Pre-pregnancy CHOLESTEROL- HDL


584
Locality type: Non-Jewish Other Rural Locality


585
Child count Ahiston drop cd


586
Mother Pre-pregnancy PROGESTERONE


587
Mother 0-12 weeks T4- FREE


588
Mother 12-24 weeks BASO abs


589
Child diagnosed Other and unspec.noninfectious gastroenteritis



and colitis


590
Child diagnosed Asthma, unspecified


591
Mother Pre-pregnancy ANTITHROMBIN-III


592
Mother 24-40 weeks TOXOPLASMA IgG


593
Mother 0-12 weeks PT-SEC


594
Child diagnosed Volume depletion disorder


595
Mother Pre-pregnancy CONTROL PTT


596
Mother 24-40 weeks EOSINOPHILS %-DIF


597
Mother Pre-pregnancy 17-OH-PROGESTERONE


598
Father count Cholesterol/hdl


599
Mother Pre-pregnancy IRON


600
Mother Pre-pregnancy HEMOGLOBIN A1C %


601
Mother 12-24 weeks HYPER %


602
Mother 0-12 weeks BASO abs


603
Locality type: Non-Jewish Locality 2,000-4,999 residents


604
Mother Pre-pregnancy APTT-sec


605
Mother count Fluticasone


606
Mother 24-40 weeks HCT/HGB Ratio


607
Father count Bezafibrate


608
Locality type: Jewish Locality 200,000-499,999 residents


609
Father diagnosed Obesity (bmi >30)


610
Mother count Omeprazole


611
Child count Co-amoxiclav cd


612
Mother 24-40 weeks PT-INR


613
Mother Pre-pregnancy HCT/HGB Ratio


614
Child count Montelukast


615
Child diagnosed Infectious colitis, enteritis, and gastroenteritis


616
Mother Pre-Pregnancy Weight count


617
Mother count Estradiol


618
Mother 24-40 weeks PCT


619
Mother Pre-pregnancy T3-TOTAL


620
Mother count Follitropin alfa


621
Child diagnosed Acute bronchitis


622
Ethnicity: Yemen


623
Child diagnosed Abdominal pain


624
Child diagnosed Other and unspecified injury to unspecified site


625
Child count Prothiazine/promethazine expectorant cd


626
Mother 24-40 weeks PT %


627
Locality type: Moshav


628
Mother Pre-pregnancy VLDL


629
Mother 24-40 weeks POTASSIUM


630
Child count Co-trimoxazole cd


631
Mother 12-24 weeks HbF


632
Mother 24-40 weeks BILIRUBIN INDIRECT


633
Mother 24-40 weeks GLOM.FILTR.RATE


634
Mother 24-40 weeks PHOSPHORUS


635
Father max Cholesterol/hdl


636
Child diagnosed Iron deficiency anemia, unspecified


637
Mother Pre-pregnancy ALY %


638
Child diagnosed Rash and other nonspecific skin eruption


639
Mother 0-12 weeks PT %


640
Mother 12-24 weeks PT %


641
Mother 24-40 weeks TRANSFERRIN


642
Father Weight count


643
Child diagnosed Late effect of injury to cranial nerve


644
Mother Pre-pregnancy T3- FREE


645
Mother 12-24 weeks PROTEIN-TOTAL


646
Cesarean birth


647
Mother Pre-pregnancy BASO abs


648
Mother 0-12 weeks T3- FREE


649
Mother Pre-pregnancy RDW-CV


650
Mother count Levothyroxine sodium


651
Child Sulfonamides Antibiotics prescription day counts


652
Mother 12-24 weeks ALBUMIN


653
Child diagnosed Undescended testicle


654
Mother 12-24 weeks CHOLESTEROL


655
Child diagnosed Hearing complaints


656
Mother 24-40 weeks MAGNESIUM


657
Mother 0-12 weeks PDW


658
Mother 0-12 weeks TRANSFERRIN


659
Mother 24-40 weeks HbA2


660
Mother 12-24 weeks T3- FREE


661
Mother count Aspirin


662
Mother 0-12 weeks BLOOD TYPE


663
Mother count Human menopausal gonadotrophin


664
Mother count Co-amoxiclav cd


665
Mother 24-40 weeks T4- FREE


666
Child diagnosed Contact dermatitis and other eczema, unspecified



cause


667
Mother 0-12 weeks DHEA SULPHATE


668
Child diagnosed Intestinal malabsorption


669
Mother 0-12 weeks PROLACTIN


670
Child diagnosed Blepharitis


671
Mother 24-40 weeks LYMPHOCYTES %-DIF


672
Mother 0-12 weeks FERRITIN


673
Mother count Symbicort/duoresp


674
Mother Pre-pregnancy PROTEIN C ACTIVITY


675
Mother 0-12 weeks HCT/HGB Ratio


676
Mother Pre-pregnancy CHOLESTEROL/HDL


677
Child count Metronidazole


678
Mother 12-24 weeks NORMOBLAST.abs


679
Father median Cholesterol/hdl


680
Mother 24-40 weeks ALBUMIN


681
Child diagnosed Candidiasis of skin and nails


682
Mother last Diastolic Blood Pressure 12-24 weeks


683
Mother 0-12 weeks RDW-CV


684
Mother 12-24 weeks URIC ACID


685
Apidoral given at birth


686
Mother 12-24 weeks BILIRUBIN TOTAL


687
Child diagnosed Irritable infant


688
Child diagnosed Varicella without mention of complication


689
Mother 0-12 weeks BILIRUBIN TOTAL


690
Father diagnosed Other and unspecified hyperlipidemia


691
Child diagnosed Infective otitis externa


692
Child diagnosed Insect bite


693
Mother Pre-pregnancy ANTI CARDIOLIPIN IgM


694
Child diagnosed Stenosis and insufficiency of lacrimal passages


695
Mother 24-40 weeks APTT-sec


696
Mother 24-40 weeks VITAMIN D (25-OH)


697
Mother 24-40 weeks GLOBULIN


698
Mother Pre-pregnancy CA-125


699
Child diagnosed Acute and unspecified inflammation of lacrimal



passages


700
Mother count Cetirizine


701
Child diagnosed Anal fissure


702
Child diagnosed Impetigo


703
Child diagnosed Laceration/cut


704
Mother 12-24 weeks APTT-sec


705
Mother 12-24 weeks LDH


706
Child diagnosed Contact dermatitis and other eczema


707
Mother 24-40 weeks CK—CREAT.KINASE(CPK)


708
Child diagnosed Serous otitis media; glue


709
Mother 0-12 weeks BILIRUBIN-DIRECT


710
Mother 12-24 weeks GPT (ALT)


711
Child count Fluticasone


712
Mother Pre-pregnancy APTT-R


713
Mother 24-40 weeks FIBRINOGEN CALCU


714
Mother 12-24 weeks NORMOBLAST.%


715
Child diagnosed Injuries


716
Mother 0-12 weeks CHOLESTEROL- HDL


717
Mother count Desogestrel


718
Mother Pre-pregnancy EOSINOPHILS %-DIF


719
Child diagnosed Wheezing baby syndrome


720
Mother 24-40 weeks FOLIC ACID


721
Mother Pre-pregnancy IgA


722
Child diagnosed Croup


723
Mother Pre-pregnancy PROT-S ANTIGEN (FREE


724
Mother count Lansoprazole


725
Mother 12-24 weeks CHOLESTEROL-LDL calc


726
Child diagnosed Diseases and other conditions of the tongue


727
Mother 12-24 weeks ALPHA FETOPROTEIN TM


728
Mother 12-24 weeks GLUCOSE 50 g


729
Mother 0-12 weeks HbF


730
Locality type: Collective Moshav


731
Child diagnosed Abnormal loss of weight


732
Child diagnosed Other diseases of nasal cavity and sinuses


733
Mother BMI delta 0-12 weeks to 12-24 weeks


734
Mother 0-12 weeks BILIRUBIN INDIRECT


735
Mother Weight delta 12-24 weeks to 24-40 weeks


736
Child diagnosed Acute laryngitis


737
Locality type: Jewish Locality 20,000-49,999 residents


738
Mother count Cefuroxime


739
Mother 12-24 weeks CALCIUM


740
Father diagnosed Essential hypertension


741
Mother Pre-pregnancy MONOCYTES abs-DIF


742
Child diagnosed Umbilical hernia without mention of



obstruction or gangrene


743
Child diagnosed Allergy/allergic react nos


744
Child diagnosed Congenital musculoskeletal deformities of



sternocleidomastoid


745
Child diagnosed Other speech disturbance


746
Mother 12-24 weeks RDW-CV


747
Mother 0-12 weeks PCT


748
Mother Pre-pregnancy LYMPHOCYTES %-DIF


749
Mother 24-40 weeks NORMOBLAST.abs


750
Child diagnosed Enterobiasis


751
Mother Pre-pregnancy FIBRINOGEN


752
Mother count Cefalexin


753
Child count Ceftriaxone


754
Mother Pre-pregnancy CHLORIDE


755
Mother count Progesterone


756
Locality type: Jewish Other Rural Locality


757
Child diagnosed Other and unspecified chronic nonsuppurative



otitis media


758
Mother 12-24 weeks GOT (AST)


759
Mother 12-24 weeks PDW


760
Locality type: Jewish Locality 2,000-4,999 residents


761
Father diagnosed Morbid obesity


762
Mother Pre-pregnancy BLOOD TYPE


763
Mother 0-12 weeks HbA2


764
Mother Weight delta 0-12 weeks to 12-24 weeks


765
Mother 24-40 weeks NON-HDL_CHOLESTEROL


766
Mother 12-24 weeks HDW


767
Mother Pre-pregnancy GLOM.FILTR.RATE


768
Child diagnosed Otalgia


769
Child diagnosed Unspecified otitis media


770
Premature birth


771
Child diagnosed Unsp.adv.effect of drug, medicinal/biological



substance n.e.s.


772
Mother Pre-pregnancy VITAMIN D (25-OH)


773
Mother 24-40 weeks CHOLESTEROL-LDL calc


774
Mother 12-24 weeks CHLORIDE


775
Born in Israel


776
Mother 12-24 weeks CHOLESTEROL- HDL


777
Mother Pre-pregnancy HbA2


778
Mother 0-12 weeks CHLORIDE


779
Locality type: Communal Locality


780
Mother Pre-pregnancy LIC


781
Locality type: Jewish Locality 5,000-9,999 residents


782
Mother 24-40 weeks NORMOBLAST.%


783
Locality type: Jewish Locality 500,000 and more residents


784
Locality type: Kibbutz


785
Locality type: Moshav 2,000-4,999 residents


786
Mother 0-12 weeks NORMOBLAST.%


787
Mother Pre-pregnancy NORMOBLAST.%


788
Locality type: Non-Jewish Locality 20,000-49,999 residents


789
Child diagnosed Urticaria


790
Mother Pre-pregnancy LIC %


791
Mother 24-40 weeks LI


792
Mother Pre-pregnancy NEUTROPHILS abs-DIF


793
Mother Pre-pregnancy TOXOPLASMA IgG


794
Locality type: Non-Jewish Locality 50,000-99,999 residents


795
Mother 24-40 weeks CONTROL PTT


796
Mother 12-24 weeks NON-HDL_CHOLESTEROL


797
Mother Pre-pregnancy HbF


798
Child diagnosed Vomiting (excl.preg. w06)


799
Mother Pre-pregnancy NEUTROPHILS %-DIF


800
Father Height count


801
Mother Pre-pregnancy MONOCYTES %-DIF


802
Mother Pre-pregnancy LYMPHOCYTES abs-DIF


803
Mother 12-24 weeks PHOSPHORUS


804
Mother 12-24 weeks HbA


805
Mother Pre-pregnancy HEMOGLOBIN A


806
Mother 24-40 weeks GGT


807
Mother 12-24 weeks BILIRUBIN-DIRECT


808
Ethnicity: Africa


809
Mother 0-12 weeks HbA


810
Child diagnosed Viral pneumonia


811
Ethnicity: Mediterranean


812
Child diagnosed Viral exanthem, unspecified


813
Mother 24-40 weeks FIBRINOGEN


814
Ethnicity: Latin America


815
Child diagnosed Torticollis, unspecified


816
Child diagnosed Congenital dislocation of hip


817
Mother 0-12 weeks NORMOBLAST.abs


818
Mother count Carbamazepine


819
Mother count Norgestimate and ethinylestradiol


820
Mother count Norethisterone


821
Mother count Nitrofurantoin


822
Mother count Metronidazole


823
Mother count Methylphenidate


824
Mother count Medroxyprogesterone


825
Mother count Loratadine


826
Mother count Ipratropium bromide


827
Mother count Gestodene and ethinylestradiol


828
Mother count Follitropin beta


829
Mother count Fluoxetine


830
Mother count Fluconazole


831
Mother count Fexofenadine


832
Mother count Famotidine


833
Mother count Escitalopram


834
Mother 0-12 weeks PT-INR


835
Mother count Dydrogesterone


836
Mother count Drospirenone and ethinylestradiol


837
Mother count Doxycycline


838
Mother count Dexamethasone


839
Mother count Desogestrel and ethinylestradiol


840
Mother count Desloratadine


841
Mother count Colchicine


842
Mother count Clonazepam


843
Mother count Clomifene


844
Mother count Clarithromycin


845
Mother count Citalopram


846
Mother count Ciprofloxacin


847
Mother count Chorionic gonadotrophin


848
Mother count Paroxetine


849
Child diagnosed Hand, foot, and mouth disease


850
Mother count Prednisone


851
Mother 12-24 weeks TRANSFERRIN


852
Child diagnosed Chronic serous otitis media


853
Child diagnosed Cellulitis and abscess of unspecified sites


854
Child diagnosed Cellulitis and abscess of finger


855
Child diagnosed Candidiasis of unspecified site


856
Child diagnosed Candidiasis of mouth


857
Child diagnosed Blisters with epidermal loss, burn



2nd.deg.unspecified site


858
Child diagnosed Convulsions


859
Child diagnosed Delivery in a completely normal case


860
Child diagnosed Anemia other/unspecified


861
Child diagnosed Allergy, unspecified, not elsewhere classified


862
Child diagnosed Allergic rhinitis


863
Child diagnosed Agranulocytosis


864
Child diagnosed Dermatophytosis of the body


865
Child diagnosed Disorders relating to other preterm infants


866
Mother count Progyluton cd


867
Child diagnosed Enteritis due to specified virus


868
Child diagnosed Acute myringitis without mention of otitis media


869
Child diagnosed Acute laryngotracheitis


870
Child diagnosed Feeding difficulties and mismanagement


871
Child diagnosed Acquired deformities of other parts of limbs


872
Child diagnosed Accident/injury; nos


873
Child diagnosed Abnormal weight gain


874
Mother count Triptorelin


875
Mother count Simvastatin


876
Mother count Sertraline


877
Mother count Seretide cd


878
Mother count Salbutamol


879
Child diagnosed Gastrointestinal hemorrhage


880
Mother count Choriogonadotropin alfa


881
Child diagnosed Hemangioma of unspecified site


882
Child diagnosed Tongue tie


883
Mother count Budesonide


884
Child diagnosed Nonsuppurative otitis media, not specified as



acute or chronic


885
Child diagnosed Open wound of face, without mention of



complication


886
Mother 12-24 weeks GLOBULIN


887
Child diagnosed Other serum reaction, not elsewhere classified


888
Child diagnosed Other specified erythematous conditions


889
Mother 12-24 weeks BILIRUBIN INDIRECT


890
Child diagnosed Other specified viral exanthemata


891
Child diagnosed Other symptoms involving digestive system


892
Father count Rosuvastatin


893
Father count Ramipril-hydrochlorothiazide cd


894
Father count Ramipril


895
Father count Propranolol


896
Father count Nifedipine-cd


897
Father count Nifedipine


898
Father count Metformin and sitagliptin cd


899
Mother 0-12 weeks GLOM.FILTR.RATE


900
Father count Insulin glargine


901
Child diagnosed Posttraumatic wound infection not elsewhere



classified


902
Father count Bisoprolol


903
Father count Atorvastatin


904
Father count Atenolol


905
Child diagnosed Premat/immature liveborn infant


906
Child diagnosed Seborrhea


907
Child diagnosed Seborrheic dermatitis, unspecified


908
Mother 12-24 weeks RUBELLA Ab IgG


909
Child diagnosed Sneezing/nasal congestion


910
Child diagnosed Stomatitis


911
Child diagnosed Strabismus and other disorders of binocular eye



movements


912
Mother Pre-pregnancy NORMOBLAST.abs


913
Child diagnosed Nervousness


914
Child diagnosed Laxity of ligament


915
Mother 0-12 weeks ESR


916
Child diagnosed Hypermetropia


917
Mother count Bethamethasone


918
Mother count Anti-d (rh) immunoglobulin


919
Mother count Aciclovir


920
Child diagnosed Herpangina


921
Mother 12-24 weeks BLOOD TYPE


922
Mother 24-40 weeks BLOOD TYPE


923
Child count Ranitidine


924
Child count Phenoxymethylpenicillin


925
Child count Mebendazole


926
Child count Loratadine


927
Child diagnosed Hip symptoms/complaints


928
Child diagnosed Hydrocele


929
Child diagnosed Hydronephrosis


930
Child count Cefaclor


931
Mother 12-24 weeks HCT/HGB Ratio


932
Child diagnosed Infectious mononucleosis


933
Child count Aciclovir


934
Father diagnosed Unspecified essential hypertension


935
Father diagnosed Overweight (bmi <30)


936
Father diagnosed Other abnormal glucose


937
Father diagnosed Lipid metabolism disorder


938
Father diagnosed Impaired fasting glucose


939
Father diagnosed Disorders of lipoid metabolism


940
Father diagnosed Diabetes mellitus without mention of



complication


941
Child diagnosed Inguinal hernia, without mention of obstruction or



gangrene


942
Father diagnosed Adult-onset type diabetes mellitus whithout



complication


943
Child diagnosed Insect bite, nonvenomous face, neck, scalp



without infection


944
Child diagnosed Jaundice, unspecified, not of newborn


945
Mother count Lamotrigine









Table 1.2 presents a list of 620 parameters from which parameters for feeing the machine learning procedure can be selected when the subject is when the subject is an unborn subject. The list is sorted according the significance of the respective feature for predicting the likelihood for childhood obesity, in descending order, so that from the standpoint of prediction accuracy it is more preferred to select a parameter that is listed higher in Table 1.2, than a parameter that is listed lower in Table 1.2. For example, when N parameters are used, it is preferred to select those parameters from lines 1 through M of Table 1.2, where N≤M≤620.










TABLE 1.2





No.
Parameter
















1
Siblings median BMI zscore mean


2
Siblings mean BMI zscore mean


3
Siblings max BMI zscore mean


4
Father BMI median


5
Father BMI max


6
Siblings at 5 years of age BMI zscore mean


7
Siblings min BMI zscore mean


8
Father BMI mean


9
Father BMI min


10
Mother Pre-Pregnancy BMI max


11
Mother Pre-Pregnancy BMI median


12
Mother 24-40 weeks MCV


13
Mother Pre-Pregnancy BMI mean


14
Mother 24-40 weeks MCH


15
Age of Father at birth


16
Siblings count BMI zscore std


17
Mother Pre-Pregnancy BMI min


18
Mother last BMI 24-40 weeks


19
Age of Mother at birth


20
Father Weight median


21
Mother Pre-Pregnancy Weight max


22
Mother last BMI 0-12 weeks


23
Father Height median


24
Mother Pre-Pregnancy Weight mean


25
Mother 12-24 weeks VITAMIN B12


26
Mother 0-12 weeks MCH


27
Father std Cholesterol


28
Mother Pre-Pregnancy Weight median


29
Siblings min BMI zscore std


30
Mother Pre-Pregnancy Weight min


31
Mother Pre-pregnancy CMV IgG


32
Mother Pre-pregnancy PDW


33
Mother 24-40 weeks GLUCOSE 50 g


34
Mother Pre-pregnancy GGT


35
Father Height mean


36
Siblings mean BMI zscore std


37
Father max Triglycerides


38
Mother 12-24 weeks RBC


39
Mother 0-12 weeks WBC


40
Siblings std BMI zscore mean


41
Mother last Diastolic Blood Pressure 24-40 weeks


42
Mother 12-24 weeks HB


43
Mother 12-24 weeks LUC %


44
Mother 0-12 weeks VITAMIN B12


45
Mother 0-12 weeks HCT


46
Mother Pre-pregnancy GLUCOSE 50 g


47
Father mean Cholesterol- hdl


48
Father mean Triglycerides


49
Father Height min


50
Siblings count BMI zscore mean


51
Mother 0-12 weeks LYMP.abs


52
Mother Pre-pregnancy GLUCOSE


53
Mother last BMI 12-24 weeks


54
Father std Glucose


55
Mother Pre-pregnancy CK—CREAT.KINASE(CPK)


56
Father std Cholesterol-ldl calc


57
Father min Cholesterol- hdl


58
Mother last BMI Pre-pregnancy


59
Mother Pre-pregnancy TSH


60
Mother last Weight Pre-pregnancy


61
Mother Pre-pregnancy MCHC


62
Mother Pre-pregnancy LYMP.abs


63
Siblings median BMI zscore std


64
Mother 12-24 weeks IRON


65
Mother count Roxithromycin


66
Mother last Weight 12-24 weeks


67
Mother 24-40 weeks MPV


68
Mother 12-24 weeks GLUCOSE


69
Mother Pre-pregnancy PT %


70
Mother 24-40 weeks VITAMIN B12


71
Father max Glucose


72
Father Weight max


73
Mother 24-40 weeks EOS %


74
Mother 24-40 weeks GLUCOSE (GTT) 0′


75
Mother Pre-pregnancy HCT


76
Mother Pre-pregnancy BILIRUBIN-DIRECT


77
Mother 0-12 weeks MPV


78
Siblings max BMI zscore std


79
Father mean Glucose


80
Mother 0-12 weeks NEUT.abs


81
Father Weight mean


82
Mother Pre-pregnancy T4- FREE


83
Mother 24-40 weeks RBC


84
Mother Pre-pregnancy LYM %


85
Mother 24-40 weeks ALK. PHOSPHATASE


86
Mother 0-12 weeks EOS.abs


87
Father min Triglycerides


88
Mother 0-12 weeks MONO.abs


89
Mother Pre-pregnancy MPV


90
Mother Pre-pregnancy NEUT %


91
Mother 24-40 weeks APTT-R


92
Siblings at 13 years of age BMI zscore mean


93
Mother Pre-pregnancy PHOSPHORUS


94
Father count Metformin


95
Mother Pre-pregnancy NEUT.abs


96
Mother 12-24 weeks MCHC


97
Mother 24-40 weeks HEMOGLOBIN A1C %


98
Mother Pre-pregnancy CHOLESTEROL-LDL calc


99
Mother last Systolic Blood Pressure 0-12 weeks


100
Father median Triglycerides


101
Mother 24-40 weeks MICRO %


102
Mother last Systolic Blood Pressure 12-24 weeks


103
Mother 24-40 weeks MONO.abs


104
Mother 12-24 weeks PLT


105
Mother Pre-pregnancy LDH


106
Mother 0-12 weeks HEPATITIS Bs Ab


107
Mother Pre-pregnancy PLT


108
Father min Glucose


109
Father max Non-hdl_cholesterol


110
Mother 12-24 weeks NEUT %


111
Mother 24-40 weeks HYPO %


112
Mother last Systolic Blood Pressure Pre-pregnancy


113
Father Height max


114
Mother last Systolic Blood Pressure 24-40 weeks


115
Father median Cholesterol- hdl


116
Mother 12-24 weeks T4- FREE


117
Mother Pre-pregnancy UREA


118
Mother Pre-pregnancy MAGNESIUM


119
Mother 0-12 weeks CHOLESTEROL/HDL


120
Mother 24-40 weeks LYM %


121
Mother 12-24 weeks MCV


122
Mother Pre-pregnancy MONO.abs


123
Mother Pre-pregnancy WBC


124
Mother 12-24 weeks MONO.abs


125
Mother 24-40 weeks HCT


126
Mother 0-12 weeks CMV IgG


127
Mother 24-40 weeks PLT


128
Mother Pre-pregnancy PROTEIN-TOTAL


129
Mother 12-24 weeks CMV IgG


130
Mother 24-40 weeks CMV IgG


131
Mother 0-12 weeks SODIUM


132
Mother 24-40 weeks NEUT %


133
Mother 24-40 weeks MCHC


134
Father Weight min


135
Mother count Amoxicillin


136
Father mean Cholesterol


137
Father median Glucose


138
Mother Pre-pregnancy CHOLESTEROL


139
Mother 0-12 weeks MONO %


140
Mother 24-40 weeks LYMP.abs


141
Mother 12-24 weeks NEUT.abs


142
Mother Pre-pregnancy HYPER %


143
Mother 12-24 weeks TSH


144
Mother count Cabergoline


145
Mother last Weight 0-12 weeks


146
Mother Pre-pregnancy PCT


147
Father Height std


148
Mother 0-12 weeks TRIGLYCERIDES


149
Mother 0-12 weeks GLUCOSE


150
Father std Cholesterol/hdl


151
Mother Pre-pregnancy HYPO %


152
Mother 24-40 weeks FERRITIN


153
Father BMI std


154
Mother Pre-pregnancy BASO %


155
Mother 24-40 weeks SODIUM


156
Mother Pre-pregnancy VITAMIN B12


157
Mother 0-12 weeks ESTRADIOL (E-2)


158
Mother 0-12 weeks LYM %


159
Mother 12-24 weeks EOS %


160
Mother 24-40 weeks NEUT.abs


161
Mother 24-40 weeks NEUTROPHILS abs-DIF


162
Father diagnosed Diabetes mellitus


163
Mother Pre-pregnancy CREATININE


164
Father Weight std


165
Mother 24-40 weeks HB


166
Mother BMI delta 12-24 weeks to 24-40 weeks


167
Mother 0-12 weeks GGT


168
Mother 0-12 weeks LH


169
Mother 24-40 weeks RDW


170
Mother 12-24 weeks HbA2


171
Mother 0-12 weeks MCV


172
Mother Pre-pregnancy MONO %


173
Mother Pre-pregnancy HB


174
Mother 24-40 weeks LUC %


175
Mother count Enoxaparin


176
Mother 24-40 weeks MONO %


177
Mother 0-12 weeks NEUT %


178
Mother 24-40 weeks WBC


179
Father mean Non-hdl_cholesterol


180
Mother 0-12 weeks EOS %


181
Mother 0-12 weeks RDW


182
Mother Pre-pregnancy RDW


183
Mother 12-24 weeks LYM %


184
Mother Pre-pregnancy SHBG


185
Mother Pre-pregnancy FOLIC ACID


186
Mother 0-12 weeks HYPO %


187
Mother Pre-pregnancy MICRO %


188
Mother 24-40 weeks BILIRUBIN TOTAL


189
Mother Pre-pregnancy SODIUM


190
Mother Pre-pregnancy RBC


191
Mother 24-40 weeks BASO %


192
Mother 24-40 weeks LYMPHOCYTES abs-DIF


193
Mother 0-12 weeks PROGESTERONE


194
Father BMI count


195
Mother Pre-pregnancy TRIGLYCERIDES


196
Father max Cholesterol


197
Mother 12-24 weeks LYMP.abs


198
Mother last Diastolic Blood Pressure 0-12 weeks


199
Mother Pre-pregnancy GLOBULIN


200
Mother 24-40 weeks CREATININE


201
Father max Cholesterol-ldl calc


202
Father max Cholesterol- hdl


203
Mother Pre-pregnancy ESR


204
Mother 12-24 weeks PT-SEC


205
Mother 24-40 weeks LUC abs


206
Mother 24-40 weeks MPXI


207
Mother Pre-Pregnancy BMI std


208
Mother 12-24 weeks FERRITIN


209
Mother 0-12 weeks MPXI


210
Mother 0-12 weeks TSH


211
Mother 24-40 weeks GOT (AST)


212
Mother 24-40 weeks HYPER %


213
Mother 24-40 weeks EOSINOPHILS abs-DIF


214
Mother 12-24 weeks WBC


215
Father mean Cholesterol-ldl calc


216
Father std Triglycerides


217
Mother Pre-pregnancy HDW


218
Mother 0-12 weeks UREA


219
Mother 12-24 weeks HCT


220
Mother Pre-pregnancy HEPATITIS Bs Ab


221
Mother 0-12 weeks LDH


222
Mother 12-24 weeks POTASSIUM


223
Mother Pre-Pregnancy Weight std


224
Mother 12-24 weeks MICRO %


225
Mother Pre-pregnancy BILIRUBIN TOTAL


226
Mother 0-12 weeks HB


227
Mother Pre-pregnancy C-REACTIVE PROTEIN


228
Mother Pre-pregnancy MCV


229
Mother Pre-pregnancy DHEA SULPHATE


230
Father min Cholesterol


231
Mother Pre-pregnancy EOS %


232
Father median Cholesterol


233
Mother 24-40 weeks BILIRUBIN-DIRECT


234
Mother 24-40 weeks STABS %-DIF


235
Siblings at 5 years of age BMI zscore std


236
Father std Cholesterol- hdl


237
Mother 12-24 weeks HYPO %


238
Mother 24-40 weeks STABS abs-DIF


239
Mother 0-12 weeks LUC %


240
Mother 12-24 weeks SODIUM


241
Mother 24-40 weeks GLUCOSE (GTT) 60′


242
Mother 24-40 weeks CHOLESTEROL


243
No. of Siblings with BMI data


244
Mother 12-24 weeks CREATININE


245
Mother 24-40 weeks GLUCOSE (GTT) 180′


246
Mother 12-24 weeks EOS.abs


247
Mother Pre-pregnancy COMPLEMENT C3


248
Mother Pre-pregnancy EOS.abs


249
Mother 24-40 weeks T3- FREE


250
Mother Pre-pregnancy FERRITIN


251
Mother Pre-pregnancy AMYLASE


252
Father count Pravastatin


253
Mother 24-40 weeks MONOCYTES abs-DIF


254
Mother 24-40 weeks GPT (ALT)


255
Mother Pre-pregnancy URIC ACID


256
Father diagnosed Obesity, unspecified


257
Mother 24-40 weeks NEUTROPHILS %-DIF


258
Mother 0-12 weeks MCHC


259
Mother 12-24 weeks MONO %


260
Mother Pre-pregnancy FIBRINOGEN CALCU


261
Mother Pre-pregnancy MPXI


262
Mother 0-12 weeks URIC ACID


263
Mother Pre-pregnancy LH


264
Mother 24-40 weeks MACRO %


265
Mother Pre-pregnancy MCH


266
Mother 24-40 weeks BASO abs


267
Father count Cholesterol-ldl calc


268
Mother 0-12 weeks MICRO %


269
Mother Weight delta Pre-pregnancy to 0-12 weeks


270
Siblings std BMI zscore std


271
Mother 24-40 weeks LDH


272
Mother 0-12 weeks PLT


273
Siblings at 13 years of age BMI zscore std


274
Father count Glucose


275
Mother Pre-pregnancy BILIRUBIN INDIRECT


276
Mother 24-40 weeks URIC ACID


277
Mother BMI delta Pre-pregnancy to 0-12 weeks


278
Mother 12-24 weeks GGT


279
Mother 0-12 weeks GPT (ALT)


280
Mother 0-12 weeks PHOSPHORUS


281
Mother Pre-pregnancy LUC %


282
Mother 0-12 weeks HYPER %


283
Mother 0-12 weeks CREATININE


284
Mother 12-24 weeks MICRO %/HYPO %


285
Mother 0-12 weeks MACRO %


286
Mother 12-24 weeks RDW


287
Mother Pre-pregnancy POTASSIUM


288
Mother 0-12 weeks RBC


289
Mother Pre-pregnancy ALK. PHOSPHATASE


290
Mother Pre-pregnancy ALBUMIN


291
Mother 12-24 weeks TRIGLYCERIDES


292
Mother 0-12 weeks AMYLASE


293
Father min Cholesterol-ldl calc


294
Mother 0-12 weeks ALK. PHOSPHATASE


295
Mother Pre-pregnancy PT-SEC


296
Mother 0-12 weeks VITAMIN D (25-OH)


297
Mother 12-24 weeks MCH


298
Mother Pre-pregnancy CALCIUM


299
Father count Cholesterol- hdl


300
Father median Cholesterol-ldl calc


301
Mother Pre-pregnancy COMPLEMENT C4


302
Mother count Ofloxacin


303
Mother last Weight 24-40 weeks


304
Mother 0-12 weeks CHOLESTEROL-LDL calc


305
Mother Pre-pregnancy MACRO %


306
Mother count Phenoxymethylpenicillin


307
Mother 0-12 weeks HDW


308
Mother 24-40 weeks TRIGLYCERIDES


309
Mother Pre-pregnancy TESTOSTERONE- TOTAL


310
Father std Non-hdl_cholesterol


311
Mother 0-12 weeks NON-HDL_CHOLESTEROL


312
Mother last Diastolic Blood Pressure Pre-pregnancy


313
Mother 0-12 weeks APTT-sec


314
Mother 24-40 weeks MICRO %/HYPO %


315
Mother 12-24 weeks MPXI


316
Mother 0-12 weeks BASO %


317
Father min Non-hdl_cholesterol


318
Mother Pre-pregnancy NON-HDL_CHOLESTEROL


319
Mother 0-12 weeks GLOBULIN


320
Mother 12-24 weeks MACRO %


321
Father count Simvastatin


322
Mother 12-24 weeks LUC abs


323
Mother 12-24 weeks PT-INR


324
Mother 0-12 weeks GOT (AST)


325
Father min Cholesterol/hdl


326
Mother 24-40 weeks GLUCOSE


327
Mother 24-40 weeks EOS.abs


328
Mother 12-24 weeks UREA


329
Mother 0-12 weeks PROTEIN-TOTAL


330
Mother Pre-pregnancy ALY


331
Mother Pre-pregnancy FREE ANDROGEN INDEX


332
Mother 0-12 weeks POTASSIUM


333
Mother 12-24 weeks AMYLASE


334
Mother 12-24 weeks CK—CREAT.KINASE(CPK)


335
Mother Pre-pregnancy GPT (ALT)


336
Mother 0-12 weeks CHOLESTEROL


337
Mother 12-24 weeks BASO %


338
Mother Pre-pregnancy CORTISOL-BLOOD


339
Mother 24-40 weeks RDW-CV


340
Mother Pre-pregnancy ESTRADIOL (E-2)


341
Mother 12-24 weeks MPV


342
Mother Pre-pregnancy PROLACTIN


343
Mother 24-40 weeks TSH


344
is Male


345
Mother 0-12 weeks CK—CREAT.KINASE(CPK)


346
Father median Non-hdl_cholesterol


347
Father mean Cholesterol/hdl


348
Mother 0-12 weeks FOLIC ACID


349
Mother 24-40 weeks IRON


350
Mother 0-12 weeks LUC abs


351
Mother Pre-pregnancy RUBELLA Ab IgG


352
Mother 0-12 weeks ALBUMIN


353
Mother 0-12 weeks IRON


354
Mother 0-12 weeks RUBELLA Ab IgG


355
Mother 24-40 weeks AMYLASE


356
Number of twin siblings


357
Mother Pre-pregnancy ANDROSTENEDIONE


358
Father count Enalapril


359
Mother count Mebendazole


360
Mother 24-40 weeks CHLORIDE


361
Mother 24-40 weeks HDW


362
Mother 24-40 weeks GLUCOSE (GTT) 120′


363
Father count Cholesterol


364
Mother 12-24 weeks PCT


365
Mother 24-40 weeks UREA


366
Mother 0-12 weeks TOXOPLASMA IgG


367
Mother Pre-pregnancy MICRO %/HYPO %


368
Mother 24-40 weeks PROTEIN-TOTAL


369
Mother 12-24 weeks TOXOPLASMA IgG


370
Mother 0-12 weeks FSH


371
Father count Non-hdl_cholesterol


372
Mother 24-40 weeks CHOLESTEROL- HDL


373
Mother 24-40 weeks PT-SEC


374
Mother Pre-pregnancy ANTI CARDIOLIPIN IgG


375
Mother Pre-Pregnancy BMI count


376
Mother 24-40 weeks PDW


377
Mother 24-40 weeks MONOCYTES %-DIF


378
Mother 0-12 weeks MICRO %/HYPO %


379
Mother Pre-pregnancy TRANSFERRIN


380
Mother Pre-pregnancy GOT (AST)


381
Mother Pre-pregnancy PT-INR


382
Mother 24-40 weeks CALCIUM


383
Mother 0-12 weeks HEMOGLOBIN A


384
Mother Pre-pregnancy LUC abs


385
Father count Amlodipine


386
Mother 12-24 weeks ALK. PHOSPHATASE


387
Father count Triglycerides


388
Mother 0-12 weeks CALCIUM


389
Mother 12-24 weeks FOLIC ACID


390
Mother Pre-pregnancy FSH


391
Mother Pre-pregnancy CHOLESTEROL- HDL


392
Mother Pre-pregnancy PROGESTERONE


393
Mother 0-12 weeks T4- FREE


394
Mother 12-24 weeks BASO abs


395
Mother Pre-pregnancy ANTITHROMBIN-III


396
Mother 24-40 weeks TOXOPLASMA IgG


397
Mother 0-12 weeks PT-SEC


398
Mother Pre-pregnancy CONTROL PTT


399
Mother 24-40 weeks EOSINOPHILS %-DIF


400
Mother Pre-pregnancy 17-OH-PROGESTERONE


401
Father count Cholesterol/hdl


402
Mother Pre-pregnancy IRON


403
Mother Pre-pregnancy HEMOGLOBIN A1C %


404
Mother 12-24 weeks HYPER %


405
Mother 0-12 weeks BASO abs


406
Mother Pre-pregnancy APTT-sec


407
Mother count Fluticasone


408
Mother 24-40 weeks HCT/HGB Ratio


409
Father count Bezafibrate


410
Father diagnosed Obesity (bmi >30)


411
Mother count Omeprazole


412
Mother 24-40 weeks PT-INR


413
Mother Pre-pregnancy HCT/HGB Ratio


414
Mother Pre-Pregnancy Weight count


415
Mother count Estradiol


416
Mother 24-40 weeks PCT


417
Mother Pre-pregnancy T3-TOTAL


418
Mother count Follitropin alfa


419
Mother 24-40 weeks PT %


420
Mother Pre-pregnancy VLDL


421
Mother 24-40 weeks POTASSIUM


422
Mother 12-24 weeks HbF


423
Mother 24-40 weeks BILIRUBIN INDIRECT


424
Mother 24-40 weeks GLOM.FILTR.RATE


425
Mother 24-40 weeks PHOSPHORUS


426
Father max Cholesterol/hdl


427
Mother Pre-pregnancy ALY %


428
Mother 0-12 weeks PT %


429
Mother 12-24 weeks PT %


430
Mother 24-40 weeks TRANSFERRIN


431
Father Weight count


432
Mother Pre-pregnancy T3- FREE


433
Mother 12-24 weeks PROTEIN-TOTAL


434
Mother Pre-pregnancy BASO abs


435
Mother 0-12 weeks T3- FREE


436
Mother Pre-pregnancy RDW-CV


437
Mother count Levothyroxine sodium


438
Mother 12-24 weeks ALBUMIN


439
Mother 12-24 weeks CHOLESTEROL


440
Mother 24-40 weeks MAGNESIUM


441
Mother 0-12 weeks PDW


442
Mother 0-12 weeks TRANSFERRIN


443
Mother 24-40 weeks HbA2


444
Mother 12-24 weeks T3- FREE


445
Mother count Aspirin


446
Mother 0-12 weeks BLOOD TYPE


447
Mother count Human menopausal gonadotrophin


448
Mother count Co-amoxiclav cd


449
Mother 24-40 weeks T4- FREE


450
Mother 0-12 weeks DHEA SULPHATE


451
Mother 0-12 weeks PROLACTIN


452
Mother 24-40 weeks LYMPHOCYTES %-DIF


453
Mother 0-12 weeks FERRITIN


454
Mother count Symbicort/duoresp


455
Mother Pre-pregnancy PROTEIN C ACTIVITY


456
Mother 0-12 weeks HCT/HGB Ratio


457
Mother Pre-pregnancy CHOLESTEROL/HDL


458
Mother 12-24 weeks NORMOBLAST.abs


459
Father median Cholesterol/hdl


460
Mother 24-40 weeks ALBUMIN


461
Mother last Diastolic Blood Pressure 12-24 weeks


462
Mother 0-12 weeks RDW-CV


463
Mother 12-24 weeks URIC ACID


464
Apidoral given at birth


465
Mother 12-24 weeks BILIRUBIN TOTAL


466
Mother 0-12 weeks BILIRUBIN TOTAL


467
Father diagnosed Other and unspecified hyperlipidemia


468
Mother Pre-pregnancy ANTI CARDIOLIPIN IgM


469
Mother 24-40 weeks APTT-sec


470
Mother 24-40 weeks VITAMIN D (25-OH)


471
Mother 24-40 weeks GLOBULIN


472
Mother Pre-pregnancy CA-125


473
Mother count Cetirizine


474
Mother 12-24 weeks APTT-sec


475
Mother 12-24 weeks LDH


476
Mother 24-40 weeks CK—CREAT.KINASE(CPK)


477
Mother 0-12 weeks BILIRUBIN-DIRECT


478
Mother 12-24 weeks GPT (ALT)


479
Mother Pre-pregnancy APTT-R


480
Mother 24-40 weeks FIBRINOGEN CALCU


481
Mother 12-24 weeks NORMOBLAST.%


482
Mother 0-12 weeks CHOLESTEROL- HDL


483
Mother count Desogestrel


484
Mother Pre-pregnancy EOSINOPHILS %-DIF


485
Mother 24-40 weeks FOLIC ACID


486
Mother Pre-pregnancy IgA


487
Mother Pre-pregnancy PROT-S ANTIGEN (FREE


488
Mother count Lansoprazole


489
Mother 12-24 weeks CHOLESTEROL-LDL calc


490
Mother 12-24 weeks ALPHA FETOPROTEIN TM


491
Mother 12-24 weeks GLUCOSE 50 g


492
Mother 0-12 weeks HbF


493
Mother BMI delta 0-12 weeks to 12-24 weeks


494
Mother 0-12 weeks BILIRUBIN INDIRECT


495
Mother Weight delta 12-24 weeks to 24-40 weeks


496
Mother count Cefuroxime


497
Mother 12-24 weeks CALCIUM


498
Father diagnosed Essential hypertension


499
Mother Pre-pregnancy MONOCYTES abs-DIF


500
Mother 12-24 weeks RDW-CV


501
Mother 0-12 weeks PCT


502
Mother Pre-pregnancy LYMPHOCYTES %-DIF


503
Mother 24-40 weeks NORMOBLAST.abs


504
Mother Pre-pregnancy FIBRINOGEN


505
Mother count Cefalexin


506
Mother Pre-pregnancy CHLORIDE


507
Mother count Progesterone


508
Mother 12-24 weeks GOT (AST)


509
Mother 12-24 weeks PDW


510
Father diagnosed Morbid obesity


511
Mother Pre-pregnancy BLOOD TYPE


512
Mother 0-12 weeks HbA2


513
Mother Weight delta 0-12 weeks to 12-24 weeks


514
Mother 24-40 weeks NON-HDL_CHOLESTEROL


515
Mother 12-24 weeks HDW


516
Mother Pre-pregnancy GLOM.FILTR.RATE


517
Premature birth


518
Mother Pre-pregnancy VITAMIN D (25-OH)


519
Mother 24-40 weeks CHOLESTEROL-LDL calc


520
Mother 12-24 weeks CHLORIDE


521
Born in Israel


522
Mother 12-24 weeks CHOLESTEROL- HDL


523
Mother Pre-pregnancy HbA2


524
Mother 0-12 weeks CHLORIDE


525
Mother Pre-pregnancy LIC


526
Mother 24-40 weeks NORMOBLAST.%


527
Mother 0-12 weeks NORMOBLAST.%


528
Mother Pre-pregnancy NORMOBLAST.%


529
Mother Pre-pregnancy LIC %


530
Mother 24-40 weeks LI


531
Mother Pre-pregnancy NEUTROPHILS abs-DIF


532
Mother Pre-pregnancy TOXOPLASMA IgG


533
Mother 24-40 weeks CONTROL PTT


534
Mother 12-24 weeks NON-HDL_CHOLESTEROL


535
Mother Pre-pregnancy HbF


536
Mother Pre-pregnancy NEUTROPHILS %-DIF


537
Father Height count


538
Mother Pre-pregnancy MONOCYTES %-DIF


539
Mother Pre-pregnancy LYMPHOCYTES abs-DIF


540
Mother 12-24 weeks PHOSPHORUS


541
Mother 12-24 weeks HbA


542
Mother Pre-pregnancy HEMOGLOBIN A


543
Mother 24-40 weeks GGT


544
Mother 12-24 weeks BILIRUBIN-DIRECT


545
Mother 0-12 weeks HbA


546
Mother 24-40 weeks FIBRINOGEN


547
Mother 0-12 weeks NORMOBLAST.abs


548
Mother count Carbamazepine


549
Mother count Norgestimate and ethinylestradiol


550
Mother count Norethisterone


551
Mother count Nitrofurantoin


552
Mother count Metronidazole


553
Mother count Methylphenidate


554
Mother count Medroxyprogesterone


555
Mother count Loratadine


556
Mother count Ipratropium bromide


557
Mother count Gestodene and ethinylestradiol


558
Mother count Follitropin beta


559
Mother count Fluoxetine


560
Mother count Fluconazole


561
Mother count Fexofenadine


562
Mother count Famotidine


563
Mother count Escitalopram


564
Mother 0-12 weeks PT-INR


565
Mother count Dydrogesterone


566
Mother count Drospirenone and ethinylestradiol


567
Mother count Doxycycline


568
Mother count Dexamethasone


569
Mother count Desogestrel and ethinylestradiol


570
Mother count Desloratadine


571
Mother count Colchicine


572
Mother count Clonazepam


573
Mother count Clomifene


574
Mother count Clarithromycin


575
Mother count Citalopram


576
Mother count Ciprofloxacin


577
Mother count Chorionic gonadotrophin


578
Mother count Paroxetine


579
Mother count Prednisone


580
Mother 12-24 weeks TRANSFERRIN


581
Mother count Progyluton cd


582
Mother count Triptorelin


583
Mother count Simvastatin


584
Mother count Sertraline


585
Mother count Seretide cd


586
Mother count Salbutamol


587
Mother count Choriogonadotropin alfa


588
Mother count Budesonide


589
Mother 12-24 weeks GLOBULIN


590
Mother 12-24 weeks BILIRUBIN INDIRECT


591
Father count Rosuvastatin


592
Father count Ramipril-hydrochlorothiazide cd


593
Father count Ramipril


594
Father count Propranolol


595
Father count Nifedipine-cd


596
Father count Nifedipine


597
Father count Metformin and sitagliptin cd


598
Mother 0-12 weeks GLOM.FILTR.RATE


599
Father count Insulin glargine


600
Father count Bisoprolol


601
Father count Atorvastatin


602
Father count Atenolol


603
Mother 12-24 weeks RUBELLA Ab IgG


604
Mother Pre-pregnancy NORMOBLAST.abs


605
Mother 0-12 weeks ESR


606
Mother count Bethamethasone


607
Mother count Anti-d (rh) immunoglobulin


608
Mother count Aciclovir


609
Mother 12-24 weeks BLOOD TYPE


610
Mother 24-40 weeks BLOOD TYPE


611
Mother 12-24 weeks HCT/HGB Ratio


612
Father diagnosed Unspecified essential hypertension


613
Father diagnosed Overweight (bmi <30)


614
Father diagnosed Other abnormal glucose


615
Father diagnosed Lipid metabolism disorder


616
Father diagnosed Impaired fasting glucose


617
Father diagnosed Disorders of lipoid metabolism


618
Father diagnosed Diabetes mellitus without mention of



complication


619
Father diagnosed Adult-onset type diabetes mellitus whithout



complication


620
Mother count Lamotrigine









Table 1.3 presents a list of 66 response parameters from which parameter to be included in questionnaire can be selected when the subject is an infant or toddler subject. The questionnaire can presented to a person on behalf of the subject, and can provide response parameters for feeing the machine learning procedure. The list is sorted according the significance of the respective feature for predicting the likelihood for childhood obesity, in descending order, so that from the standpoint of prediction accuracy it is more preferred to select a parameter that is listed higher in Table 1.3, than a parameter that is listed lower in Table 1.3. For example, when N parameters are used, it is preferred to select those parameters from lines 1 through M of Table 1.3, where N≤M≤66.










TABLE 1.3





No.
Parameter
















1
Last WFL zscore


2
Siblings mean BMI zscore mean


3
Father BMI mean


4
Weight Routine checkup - 18-22 months


5
Weight Routine checkup - 12-16 months


6
Weight Routine checkup - 4-6 months


7
Ethnicity: North Africa


8
Weight Routine checkup - 9-12 months


9
WFL Routine checkup - 18-22 months


10
WFL Routine checkup - 12-16 months


11
WFL Routine checkup - 1-2 months


12
Mother last BMI Pre-pregnancy


13
Date of Birth


14
WFL Routine checkup - 9-12 months


15
Age of Father at birth


16
Siblings mean BMI zscore std


17
Age of Mother at birth


18
Ethnicity: West Europe


19
Weight Routine checkup - 6-9 months


20
WFL Routine checkup - 4-6 months


21
Father Weight mean


22
WFL Routine checkup - 2-3 months


23
Mother last BMI 0-12 weeks


24
Mother last Weight Pre-pregnancy


25
Ethnicity: North America


26
Mother last BMI 24-40 weeks


27
No. of Siblings with BMI data


28
Weight Routine checkup - 2-3 months


29
Ethnicity: Unknown


30
WFL Routine checkup - 6-9 months


31
Height Routine checkup - 12-16 months


32
Ethnicity: Ethiopia


33
Height Routine checkup - 18-22 months


34
Ethnicity: East Europe


35
Week of year bom


36
Birth weight


37
Mother last BMI 12-24 weeks


38
Weight Routine checkup - 1-2 months


39
Height Routine checkup - 9-12 months


40
Age at last WFL


41
Age at Target measurement


42
Mother last Weight 12-24 weeks


43
Height Routine checkup - 2-3 months


44
Height Routine checkup - 6-9 months


45
Ethnicity: Iraq


46
Ethnicity: Muslim Arab


47
Height Routine checkup - 4-6 months


48
Mother BMI delta 12-24 weeks to 24-40 weeks


49
Height Routine checkup - 1-2 months


50
Mother last Weight 0-12 weeks


51
Ethnicity: Iran


52
Mother BMI delta Pre-pregnancy to 0-12 weeks


53
Mother last Weight 24-40 weeks


54
Mother Weight delta Pre-pregnancy to 0-12 weeks


55
Ethnicity: Asian


56
Ethnicity: Yemen


57
is Male


58
Mother Weight delta 0-12 weeks to 12-24 weeks


59
Ethnicity: USSR


60
Ethnicity: Mediterranean


61
Mother Weight delta 12-24 weeks to 24-40 weeks


62
Mother BMI delta 0-12 weeks to 12-24 weeks


63
Ethnicity: Latin America


64
Born in Israel


65
Premature birth


66
Ethnicity: Africa









Table 1.4 presents a list of 21 response parameters from which parameter to be included in questionnaire can be selected when the subject is an unborn subject. The questionnaire can presented to a person on behalf of the subject, and can provide response parameters for feeing the machine learning procedure. The list is sorted according the significance of the respective feature for predicting the likelihood for childhood obesity, in descending order, so that from the standpoint of prediction accuracy it is more preferred to select a parameter that is listed higher in Table 1.4, than a parameter that is listed lower in Table 1.4. For example, when N parameters are used, it is preferred to select those parameters from lines 1 through M of Table 1.4, where N≤M≤21.










TABLE 1.4





No.
Parameter
















1
Siblings mean BMI zscore mean


2
Father BMI mean


3
Mother last BMI Pre-pregnancy


4
Age of Father at birth


5
Siblings mean BMI zscore std


6
Age of Mother at birth


7
Father Weight mean


8
Mother last BMI 0-12 weeks


9
Mother last Weight Pre-pregnancy


10
Mother last BMI 24-40 weeks


11
No. of Siblings with BMI data


12
Mother last BMI 12-24 weeks


13
Mother last Weight 12-24 weeks


14
Mother BMI delta 12-24 weeks to 24-40 weeks


15
Mother last Weight 0-12 weeks


16
Mother BMI delta Pre-pregnancy to 0-12 weeks


17
Mother last Weight 24-40 weeks


18
Mother Weight delta Pre-pregnancy to 0-12 weeks


19
Mother Weight delta 0-12 weeks to 12-24 weeks


20
Mother Weight delta 12-24 weeks to 24-40 weeks


21
Mother BMI delta 0-12 weeks to 12-24 weeks









Example 2

This Example describes analysis of data collected over a decade from Israel's largest healthcare provider, to assess risk factors for pediatric obesity and to develop a model for assessing children's obesity risk in order to inform and target interventions. The inventors analyzed nationwide electronic health records of children from 2006 to 2018 for whom sequential anthropometric data were available. Obesity was defined as body mass index (BMI)≥95th percentile for age and gender. Data of children and their families included anthropometric measurements, drug prescriptions, medical diagnoses, demographic data and laboratory tests.


Analysis of BMI trajectories among 382,132 adolescents revealed that among obese adolescents, the largest annual increase in BMI percentile occurs at 2-5 years of age. Therefore, the inventors devised a computational model based on data of 136,196 children from birth up to 2 years of age for predicting obesity at 5-6 years of age and from birth and up to 2 years of age. Most (51%) obese children in our cohort had a normal weight at infancy. As will be shown below, the model predicted obesity with an area under the receiver operating characteristic curve (auROC) and 95% CI of 0.803 [0.796−0.812]. Discrimination results on different subpopulations demonstrated its robustness across a clinically heterogeneous pediatric population. The most influential features included anthropometric measurements of the child and the family. Other impactful features included ethnicity and maternal pregnancy glucose measurements. A model based solely on features that are available pre-birth had similar performance to a model based on the child's last available weight and length measurements.


Methods
Study Design and Population

Extracted features included maternal, paternal and siblings' data. FIG. 3 illustrates the dataset used in the present Example. The dataset contained 1,449,442 children who have at least one measurement in a routine medical infant checkup which is scheduled for all Israeli infants at ages 1, 2, 4, 6, 9, 12, and 18 months. Of them, 643,463 children have an additional measurement between 5 and 6 years of age, which was defined as the outcome for the machine learning procedure. 136,196 children who have at least 2 different routine checkup measurements in addition to the 5-6 years old outcome measurement were included in the cohort. 90,270 children included in the cohort have maternal data, 92,152 have paternal data and 70,735 have data of at least one sibling.


Features

All EHR data available were binned into time periods and statistical measures (e.g., median, max, slope) were taken as features for each period. Pharmaceutical prescriptions and clinical diagnoses were categorized by ATC codes (Anon n.d.) and ICD9 diagnosis codes, respectively, and counts in different time periods were taken as features. Weight, height, Weight-for-Length (WFL) and BMI data were converted to reference z-scores provided by the Center for Disease Control and Prevention (CDC) (Barlow and Expert Committee 2007). Valid measurements were defined as being in the range of 5 CDC standard deviation scores for weight and height. Features from maternal pregnancy were binned in alignment with the routine pregnancy tests schedule in Israel. Specific features of interest such as antibiotic prescriptions, ethnicity, and socioeconomic status surrogates were devised manually based on domain knowledge. Altogether, 943 features were devised for each child.


The characteristics of the Study Cohort and features used are summarized in Table 2.1, below.













TABLE 2.1







Train set
Temporal test set




(n = 108,416)
(n = 27,780)



aged 5 before 2017
aged 5 at 2017
All
















Children (n = 136,196)











Obesity status at 5-6 years
Underweight
13,635
3,304
16,939


of age
Normal weight
75,648
19,867
95,515



Overweight
19,133
4,609
23,742



Obese
8,120
1,941
10,061


Sex
Female
52,733
13,458
66,191



Male
55,683
14,322
70,005







Children with maternal data (n = 90,270)











Maternal age at childbirth
mean (std)
30.1 (5.2)
30.5 (5.2)
30.1 (5.2)


[years]


Pre-pregnancy BMI
mean (std)
23.6 (4.7)
23.3 (4.4)
23.5 (4.6)


[m/kg2]







Children with paternal data (n = 92,152)











Paternal age [years]
mean (std)
33.1 (5.9)
33.3 (5.7)
33.2 (5.9)


Paternal BMI [m/kg2]
mean (std)
25.9 (4.4)
25.6 (4.2)
25.9 (4.3)







Children with Siblings data (n = 70,735)











Number of children with
count
55070
15665
70735


siblings data


Number of siblings per
mean (std)
 1.1 (1.3)
 1.3 (1.4)
 1.2 (1.3)


child


Sibling BMI CDC z-score
mean (std)
 0.0 (1.1)
−0.1 (1.1)
 0.0 (1.1)









Outcome

The outcome for the models was the obesity status of children at 5 to 6 years of age. Obesity status was defined in accordance with health care professionals in Israel, using the CDC BMI reference percentiles. Cutoffs for normal weight, overweight, and obesity were determined using the CDC's standard thresholds of the 85th percentile for overweight and 95th percentile for obesity. Using other percentiles curves such as, but not limited to, the World Health Organization (WHO) WFL, and WHO BMI provided similar estimates of obesity risk as the CDC percentiles at 5 years of age.


Statistical Analysis

Childhood Obesity Prediction Model


In this Example, Gradient Boosting trees were trained for providing the prediction. Trees allow nonlinear and multiple feature interactions to be captured, which may be important in obtaining an accurate prediction model. The parameters of the model were tuned using cross-validation on the training set. As stringent tests, both temporal and geographical validations were used, thus testing the performance of the model for distribution shifts over time and geographic location. The temporal validation set contained the most recent year in which the data were available. The geographical validation set contained all the clinics in the most populated and multiethnic city in Israel, Jerusalem. Unless stated otherwise, the reported results are on the temporal validation sets. Full results on both validation sets are available in Table 2.2, below.


As a baseline model for comparison the last WFL percentile routine checkup measurement available before 2 years of age was used, as current guidelines recommend that clinicians assess a child's current nutritional and obesity status by calculating WFL percentile or BMI percentile in children 0 to 2 years of age, or older than 2 years of age, respectively (Daniels et al. 2015). The WFL percentile thus emulates the information a caregiver has today to assess the current obesity status and future obesity risk of children younger than 2 years of age (Taveras et al. 2009). This variable also contains information of sex and age, as it standardizes by them. This variable itself is a predictor of the outcome, achieving an auROC of 0.749 and auPR of 0.223, and acts as a baseline to compare and improve upon.


Risk Factors Analysis from the Prediction Model


Risk factors were investigated by analyzing which features attribute to the model's prediction. To this end, the recently introduced SHAP (SHapley Additive exPlanation) method (Lundberg and Lee 2017; Lundberg et al. 2018) was used. The SHAP interprets the output of a machine learning model. A feature's Shapley value represents the average change in the model's output by conditioning on that feature when introducing features one at a time over all feature orderings. Shapley values were calculated individually for every child's feature. A property of Shapley values is that they are additive, meaning that the Shapley values of a child's features add up to the predicted log-odds of obesity for that child. In this Example, this value was transformed for each feature and each child to obtain a relative risk score.


Feature attributions were thus analyzed at the individual level, by examining plots of the Shapley value as a function of the feature value for all individuals. This method allowed capturing non-linear and continuous relations between a feature's impact on the prediction and the feature's value. A vertical spread in such a plot implies interaction with other features in the model, which would not have been attainable using a linear model. Building a model with many correlated features (e.g., a child's weight measurement at adjacent time points) is bound to suffer from severe collinearity of the features, and consequently the feature attributions will be spread across these related features. To tackle this, the additive property of Shapley values was used. Adding up the Shapely values of related features provided an analysis on this group of features. This provided better estimates of relevant risk scores. Another use of the additive property allows adding features according to groups and analyzing the model globally by taking the mean over absolute Shapely values of all children in each group of features. This gives insight on the impact of a feature group.


Results
Acceleration of BMI in Early Childhood

BMI trajectories were first analyzed in early childhood in relation to obesity status at 13-14 years of age. A total of 382,132 children with 1,401,803 measurements were included in the analysis (FIGS. 4A and 4B). The mean change in BMI z-score of children who were not obese at 13 years of age remained close to 0 from 1 year of age, with an annual change of less than 0.1 z-scores. However, for obese children at 13 years of age, the BMI z-score incremented throughout infancy and early childhood with the largest annual increase in BMI percentile observed at 2-5 years of age. A model has therefore been developed in accordance with some embodiments of the present invention to identify children at high risk for obesity within the subsequent 3-4 years at 2 years of age, prior to this critical time period.


The transition of obesity status over the first 6 years of life for the 136,196 children that were included in our cohort was analyzed. Obesity status was defined for each child at two time-points: the last available routine checkup before 2 years of age and at 5-6 years of age (FIG. 4C). This analysis revealed that most obese children at 5-6 years of age had normal weight at infancy (51%) (FIG. 4D).


Prediction of Childhood Obesity at 5-6 Years of Age

In accordance with some embodiments of the present invention, a model was constructed for predicting the likelihood for children at 0-2 years of age to develop childhood obesity at 5 to 6 years of age. The discrimination performance of the model was evaluated using the area under the receiver operating (auROC) and precision-recall (auPR) curves (FIGS. 5A and 5C). As shown, the technique of the present embodiments outperforms the baseline model based on the child's last WFL percentile. Both temporal and geographical validation results are summarized in Table 2.2, below.


The model of the present embodiments outputs calibrated continuous risk probabilities. Applying a clinical decision thereafter (for example, a nutritional intervention) can vary between individuals and depend on the costs and benefits of the action, both clinically and economically. Decision curves (Vickers and Elkin 2006) offer a graphical tool to analyze clinical utility of adopting a new risk prediction model. The curves contain information that can guide clinicians to make decisions based on the risk thresholds, and based on the tradeoffs (costs and benefits) of their decision to treat. The costs and benefits can be translated into a function of the optimal threshold probability. In this Example, clinical utility was analyzed by constructing decision curves (FIG. 5D). As shown, the model of the present embodiments dominates over other strategies in net benefit over all threshold probabilities, with significant margins in the lower threshold probability regime. A summary of the effect of applying different decision thresholds on the model performance is presented in Table 2.2, below.


The discrimination results (auPR) of the model of the present embodiments were further analyzed on different subpopulations of children (FIGS. 6A-C). The effect of gender on the performance of the model was evaluated. Similar results for boys and girls were found. Children who had at least one diagnosis of a complex chronic condition were evaluated using a previously defined classification system (Feudtner et al. 2014). The discrimination of the model was similar in this group, demonstrating the robustness of the model of the present embodiments across a clinically heterogeneous pediatric population. Discrimination performance was also evaluated by obesity status as defined by the last available child percentile prior to 2 years of age. The model of the present embodiments had the highest auPR in children who were obese at infancy, followed by overweight and normal weight at infancy. The model of the present embodiments outperformed the baseline model in predicting future obesity in all infants, regardless of obesity status at baseline (FIG. 6B). An increase in the number of documented anthropometric measurements during routine checkups improved the discrimination performance of the model.


As earlier detection of childhood obesity may be more beneficial and allow earlier interventions, the ability to construct a prediction model for childhood obesity at the age 5-6 years of age was analyzed in the following time points: pre-birth, birth, 6 months, 1 year and 1.5 years of age. The effect of the child's age at prediction and the model discrimination performance is presented in FIG. 8A. As shown, the model performance improved when the prediction is done at an older age, which is closer to the target age of the predictor. Note that a prediction model constructed pre-birth has an auROC of 0.708 and auPR of 0.176, very similar to the performance of the baseline model based on the child's own weight and length measurements at 1 years of age which has an auROC of 0.709 and auPR of 0.166. The model of the present embodiments thus outperformed the baseline model in the entire age range.


Features Attribution

An analysis of feature attributions was performed using Shapley values. The results of the analysis are shown in FIGS. 7A-H. FIG. 7A presents a global analysis of the model's features attributions. The mean of absolute summation of Shapley values for different groups of features is presented for the entire cohort. Feature importance dependence plots of the Shapley value were also examined as a function of the feature value for all individuals. Most of the influential features were previous anthropometric measurements of the child, with the last measured WFL percentile being the most impactful feature (FIG. 7C). Anthropometric features of parents and siblings and North African Jewish descendancy also had a significant impact on the prediction (FIGS. 7A, 7D, 7E and 7H). Interestingly, maternal blood glucose on 50 g glucose tolerance tests (GTT) were also influential for the prediction of obesity at 5-6 years of age (FIG. 7F). Relative risk for obesity has increased monotonically across all the maternal glucose spectrum and increased above 1 in values above 100 mg/dL.


Analysis of the relative importance of different groups of features at different ages of applying the predictor revealed that the most influential features at birth are anthropometric measurements of the siblings, mother and father. Following these, the influence of the child's own anthropometrics measurements becomes more substantial and is roughly equal to the contribution of all other features in 1 years of age. Laboratory tests, drugs prescriptions and diagnoses have smaller relative influence, which decreases as the data on the child's anthropometrics accumulates (FIG. 8B).


Using information on pharmaceutical prescriptions, the effect of in utero and early life antibiotic exposure was also analyzed. 83,627 children (80%) had at least one antibiotic prescription in the first 2 years of life. The analysis revealed that antibiotic exposure in utero and in the first two years of life and age of first exposure to antibiotic had no effect on obesity risk at 5-6 years of age (FIG. 7G).


Prediction Model Based on a Smaller Number of Parameters

Based on the observation that infant routine checkups, family anthropometric measurements, and ethnicity contribute most to the predictive power of the model, a simple prediction model was established based on a set of self-assessed questions that parents can easily fill out at different time points up to 2 years of age in order to assess their child's risk of obesity. This model achieved an auROC of 0.798 and auPR of 0.296, compared to 0.749 and 0.223, respectively, for the baseline model.


Discussion

This Example demonstrates a diagnostic prediction model for pediatric obesity at 5-6 years of age based on a comprehensive nationwide EHR encompassing over 10 years of children and familial data. Overweight 5-year-olds are four times more likely to become obese later in life compared to normal-weight children, and weight in this age is considered to be a good indicator of the child's future metabolic health. The target age of prediction model presented in this Example is also supported by a recently published observation on children BMI trajectories (Geserick et al. 2018), which was also replicated in our cohort, showing 2 to 6 years of age as the maximal BMI acceleration time period. The model is therefore designed to identify children at risk prior to this critical time window, in which mature eating patterns become more developed as children reduce breast milk or formula consumption. In addition, the analysis of the transition in obesity status in the first 6 years of life revealed that most obese children had normal weight at infancy, underscoring the importance of building a tool that allows clinicians to identify high risk infants that are considered to have a normal weight at infancy but will develop obesity, as they will constitute the majority of obese children in the future.


The model presented in this Example achieved an auROC of 0.803 and auPR of 0.304. Further Analysis of prediction performance on subpopulations of the cohort demonstrated robustness in discrimination performance across the entire pediatric population, including children with complex chronic diseases. Unlike previous studies (Hammond et al. 2019), the results presented in this Example were similar for boys and girls. Additional models were further devised for predicting obesity prior to two years of age. High impact of family anthropometric measurements in determining future obesity risk of the child was demonstrated. This Example showed that a prediction model constructed pre-birth, which is mainly based on family anthropometric measurements has very similar performance of predicting at 1 years of age based on the child's last available weight and length measurements. A simple self-assessed questionnaire for childhood obesity prediction pre-birth achieved an auROC of 0.798 and auPR of 0.296.


The technique presented in this Example has several advantages over previous studies. The technique presented in this Example include full data on both the child, from pregnancy to 5-6 years of age, and his family, and is the first to be validated both temporally and geographically at different clinics on a national level, thus representing a wide target population. The technique presented in this Example is the first to assess clinical utility by constructing decision curves. To date, there are no clinical guidelines defining the risk threshold for obesity prediction. The definition of this threshold may be influenced by many factors, including the characteristics of the proposed intervention, the availability of resources for intervention and the prevalence of obesity in the target population, and will impact the sensitivity and specificity of the prediction model. The decision curve analysis presented in this Example may thus help in determining risk thresholds and the clinical usefulness of the model for different interventions.


The mechanisms involved in the development of obesity in children are complex and include genetic, environmental, and developmental factors. The large cohort of Israeli children represents a diverse and multi-ethnic population with genetic heterogeneity. Not surprisingly, many of the variables found to be important in the model were directly related to the child's previous anthropometric measurements. Familial anthropometric measurements, including paternal, maternal and sibling's BMI were also important, in line with previous studies showing associations between these variables and childhood obesity. Among familial data, sibling's BMI had the highest impact on the prediction model, most likely due to both genetic and environmental influences.


There is evidence that uterine environment may cause a permanent influence on fetus future health, and may lead to enhanced susceptibility to diseases later in life. This concept is defined as ‘gestational programming’ of the fetus, and is thought to be mediated by Epigenetic mechanisms (Desai et al. 2015; Desai and Hales 1997). The data on maternal pregnancy, including lab tests, diagnoses and medications was used to analyze associations of these features to obesity status of the offspring at 5-6 years of age. One of the most prominent features in pregnancy was maternal blood glucose values (FIG. 7F). An increase in maternal blood glucose levels during pregnancy, adjusted for other features incorporated in the model (such as maternal BMI), was associated with a higher risk for childhood obesity. This association, which was apparent even in glucose values which are considered in the normal range, demonstrates that exposure to higher glucose levels in utero throughout the entire maternal glucose spectrum is significantly associated with childhood glucose and insulin resistance of the offspring and is independently associated with childhood adiposity. Ethnicity as a risk factor has previously been studied in the UK and USA populations, in which a higher prevalence of obesity was found among children of African descent (Brophy et al. 2009). The analysis presented in This Example concentrated on the Israeli population, and revealed North African Jewish descendancy as a strong contributor for predicting obesity.


The role of the gut microbiota in obesity has been vastly studied in recent years (Castaner et al. 2018). Microbiome composition undergoes many changes during the first years of life (Stewart et al. 2018). Antibiotics, which are frequently prescribed in the pediatric population (Chai et al. 2012), can significantly alter the microbiome composition (Robinson and Young 2010). Therefore, several recent studies assessed the relationship between antibiotic usage in early life and childhood obesity. These resulted in conflicting findings (Shao et al. 2017). The large sample size and the data on antibiotic prescriptions in pregnancy and infancy used in this Example allowed to explore this association. The analysis presented in this Example revealed that while the vast majority (80%) of the cohort received antibiotics at least once by the age of 2 years of age, antibiotic exposure in utero and in the first two years of life, and age of first exposure to antibiotic, had no observed impact on the obesity risk at 5-6 years of age.


The data used in This Example is from a retrospective observational EHR. These may suffer from potential biases and are affected by a variety of healthcare processes. Sampling bias was minimized by choosing children based on the schedule of routine measurements of weight and height, which includes both measurements at 0-2 years of age and a measurement at 5-6 years of age.


It is noted that while the prediction model presented in this Example is based on data of Israeli children, the validation process, which included both a temporal and a geographical validation, the well-known universal risk factors for childhood obesity that were found in the analysis of the model, and the striking similarity of the analysis on BMI trajectories to an independent, recently published German cohort (Geserick et al. 2018), indicates that the results may be generalized to other populations as well.









TABLE 2.2







Prediction Results










Temporal test set
Geographical test set











Model
auPR
auROC
auPR
auROC





Baseline
0.223
0.749
0.177
0.736



(0.209-0.235)
(0.739-0.758)
(0.162-0.201)
(0.712-0.755)


Full
0.304
0.803
0.251
0.789


Model
(0.286-0.321)
(0.796-0.812)
(0.230-0.280)
(0.771-0.805)





Abbreviations: auPR/auROC—Area under the PR/ROC curve, PR—Precision-Recall, ROC—Receiver-Operator-Characteristic













TABLE 2.3







Effects of varying decision threshold on model performance










Predicted probability threshold
















2%
5%
10%
20%
30%
40%
Baseline


















Sensitivity
0.962
0.794
0.585
0.364
0.236
0.142
0.281


Specificity
0.257
0.651
0.840
0.946
0.977
0.991
0.949


PPV
0.089
0.146
0.215
0.334
0.435
0.533
0.291


NPV
0.989
0.977
0.964
0.952
0.945
0.939
0.946


Net Benefit
0.053
0.038
0.024
0.013
0.007
0.004





Abbreviations: NPV—Negative predictive value, PPV—positive predictive value













TABLE 2.4







Prediction of obesity at 5-6 years of age prior to 2 years of age









Age of applying
Temporal test set
Geographical test set











prediction
auPR
auROC
auPR
auROC















Pre-birth
Full
0.176
0.708
0.134
0.680



Model
(0.168-0.188)
(0.689-0.723)
(0.125-0.153)
(0.660-0.704)


Birth
Full
0.177
0.711
0.134
0.684



Model
(0.169-0.189)
(0.701-0.726)
(0.124-0.153)
(0.666-0.708)


 6 months
Baseline
0.133
0.671
0.099
0.641




(0.126-0.144)
(0.666-0.681)
(0.085-0.117)
(0.620-0.669)



Full
0.230
0.759
0.174
0.728



Model
(0.216-0.249)
(0.751-0.769)
(0.153-0.200)
(0.713-0.747)


12 months
Baseline
0.166
0.709
0.130
0.684




(0.159-0.178)
(0.700-0.716)
(0.117-0.147)
(0.667-0.703)



Full
0.249
0.777
0.204
0.755



Model
(0.233-0.267)
(0.769-0.787)
(0.187-0.229)
(0.739-0.775)


18 months
Baseline
0.190
0.732
0.162
0.716




(0.179-0.201)
(0.726-0.742)
(0.147-0.184)
(0.693-0.740)



Full
0.278
0.791
0.230
0.775



Model
(0.262-0.297)
(0.783-0.800)
(0.215-0.255)
(0.759-0.792)


 2 years
Baseline
0.223
0.749
0.177
0.736




(0.209-0.235)
(0.739-0.758)
(0.162-0.201)
(0.712-0.755)



Full
0.304
0.803
0.251
0.789



Model
(0.286-0.321)
(0.796-0.812)
(0.230-0.280)
(0.771-0.805)





Abbreviations: auPR/auROC—Area under the PR/ROC curve, PR—Precision-Recall, ROC—Receiver-Operator-Characteristic






Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.


All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. In addition, any priority document(s) of this application is/are hereby incorporated herein by reference in its/their entirety.


REFERENCES



  • [1] NCD Risk Factor Collaboration (NCD-RisC) (2017). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 390, 2627-2642.

  • [2] Ebbeling, C. B., Pawlak, D. B., and Ludwig, D. S. (2002). Childhood obesity: public-health crisis, common sense cure. Lancet 360, 473-482.

  • [3] Karnik, S., and Kanekar, A. (2012). Childhood obesity: a global public health crisis. Int. J. Prev. Med. 3, 1-7.

  • [4] Young-Hyman, D., Schlundt, D. G., Herman, L., De Luca, F., and Counts, D. (2001). Evaluation of the insulin resistance syndrome in 5- to 10-year-old overweight/obese African-American children. Diabetes Care 24, 1359-1364.

  • [5] Molnár, D. (2004). The prevalence of the metabolic syndrome and type 2 diabetes mellitus in children and adolescents. Int. J. Obes. Relat. Metab. Disord. 28 Suppl 3, S70-4.

  • [6] Sawyer, M. G., Harchak, T., Wake, M., and Lynch, J. (2011). Four-year prospective study of BMI and mental health problems in young children. Pediatrics 128, 677-684.

  • [7] Jeffery, R. W., Drewnowski, A., Epstein, L. H., Stunkard, A. J., Wilson, G. T., Wing, R. R., and Hill, D. R. (2000). Long-term maintenance of weight loss: current status. Health Psychol. 19, 5-16.

  • [8] Reinehr, T., Kleber, M., Lass, N., and Toschke, A. M. (2010). Body mass index patterns over 5 y in obese children motivated to participate in a 1-y lifestyle intervention: age as a predictor of long-term success. Am. J. Clin. Nutr. 91, 1165-1171.

  • [9] He, M., and Evans, A. (2007). Are parents aware that their children are overweight or obese? Do they care? Can. Fam. Physician 53, 1493-1499.

  • [10] Patel, A. I., Madsen, K. A., Maselli, J. H., Cabana, M. D., Stafford, R. S., and Hersh, A. L. (2010). Underdiagnosis of pediatric obesity during outpatient preventive care visits. Acad. Pediatr. 10, 405-409.

  • [11] Riley, M. R., Bass, N. M., Rosenthal, P., and Merriman, R. B. (2005). Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J. Pediatr. 147, 839-842.

  • [12] Redsell, S. A., Atkinson, P. J., Nathan, D., Siriwardena, A. N., Swift, J. A., and Glazebrook, C. (2011). Preventing childhood obesity during infancy in UK primary care: a mixed-methods study of HCPs' knowledge, beliefs and practice. BMC Fam. Pract. 12, 54.

  • [13] Barlow, S. E., and Expert Committee (2007). Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120 Suppl 4, S164-92.

  • [14] Cunningham, S. A., Kramer, M. R., and Narayan, K. M. V. (2014). Incidence of childhood obesity in the United States. N. Engl. J. Med. 370, 403-411.

  • [15] Gardner, D. S. L., Hosking, J., Metcalf, B. S., Jeffery, A. N., Voss, L. D., and Wilkin, T. J. (2009). Contribution of early weight gain to childhood overweight and metabolic health: a longitudinal study (EarlyBird 36). Pediatrics 123, e67-73.

  • [16] Geserick, M., Vogel, M., Gausche, R., Lipek, T., Spielau, U., Keller, E., Pfäffle, R., Kiess, W., and Körner, A. (2018). Acceleration of BMI in early childhood and risk of sustained obesity. N. Engl. J. Med. 379, 1303-1312.

  • [17] Data—Clalit Research Institute Available at: http://clalitresearch(dot)org/about-us/our-data/ [Accessed Oct. 7, 2018].

  • [18] Daniels, S. R., Hassink, S. G., and COMMITTEE ON NUTRITION (2015). The role of the pediatrician in primary prevention of obesity. Pediatrics 136, e275-92.

  • [19] WHOCC—Structure and principles Available at: https://www(dot)whocc(dot)no/atc/structure_and_principles/ [Accessed Oct. 12, 2018].

  • [20] Fedorov, V., Mannino, F., and Zhang, R. (2009). Consequences of dichotomization. Pharm. Stat. 8, 50-61.

  • [21] Ke, G., Meng, Q., Finley, T., Wang, T., Chen, W., Ma, W., Ye, Q., and Liu, T.-Y. (2017). LightGBM: A Highly Efficient Gradient Boosting Decision Tree. undefined.

  • [22] Saito, T., and Rehmsmeier, M. (2015). The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PLoS ONE 10, e0118432.

  • [23] Steyerberg, E. W., Vickers, A. J., Cook, N. R., Gerds, T., Gonen, M., Obuchowski, N., Pencina, M. J., and Kattan, M. W. (2010). Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21, 128-138.

  • [24] Gerds, T. A., Cai, T., and Schumacher, M. (2008). The performance of risk prediction models. Biom. J. 50, 457-479.

  • [25] Niculescu-Mizil, A., and Caruana, R. (2005). Predicting good probabilities with supervised learning. In Proceedings of the 22nd international conference on Machine learning—ICML '05 (New York, N.Y., USA: ACM Press), pp. 625-632.

  • [26] Aggarwal, C. C. ed. (2015). Data Classification: Algorithms and Applications illustrated. (CRC Press).

  • [27] Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., and Collins, G. S. (2015). Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann. Intern. Med. 162, W1-73.

  • [28] Vickers, A. J., and Elkin, E. B. (2006). Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making 26, 565-574.

  • [29] Vickers, A. J., Van Calster, B., and Steyerberg, E. W. (2016). Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ 352, i6.

  • [30] Lundberg, S. M., and Lee, S.-I. (2017). A Unified Approach to Interpreting Model Predictions.

  • [31] Lundberg, S. M., Erion, G. G., and Lee, S.-I. (2018). Consistent Individualized Feature Attribution for Tree Ensembles. arXiv.


Claims
  • 1. A method of predicting likelihood for childhood obesity, comprising: obtaining a plurality of parameters, wherein at least a few of said parameters characterize an infant or toddler subject;accessing a computer readable medium storing a machine learning procedure trained for predicting likelihoods for childhood obesity;feeding said procedure with said plurality of parameters; andreceiving from said procedure an output indicative of a likelihood that said infant or toddler subject is expected to develop childhood obesity, wherein said output is related non-linearly to said parameters.
  • 2. The method according to claim 1, wherein said plurality of parameters comprises at least one parameter extracted from an electronic health record associated with said infant or toddler subject.
  • 3. The method according to claim 1, comprising presenting to a user, by a user interface, a questionnaire and a set of questionnaire controls, receiving a set of response parameters entered by said user using said questionnaire controls, wherein said plurality of parameters comprises said response parameters.
  • 4. The method according to claim 1, wherein said plurality of parameters comprises at least one parameter extracted from a body liquid test applied to said infant or toddler subject.
  • 5. The method according to claim 1, wherein said plurality of parameters comprises at least one parameter characterizing a parent or a sibling of said infant or toddler subject.
  • 6. The method according to claim 5, wherein said at least one parameter characterizing said parent comprise a parameter extracted from a body liquid test applied to said parent or sibling.
  • 7. The method according to claim 1, wherein said plurality of parameters comprises at least one parameter extracted from a diagnosis previously recorded for said subject.
  • 8. The method according to claim 1, wherein said plurality of parameters comprises at least one parameter indicative of a pharmaceutical prescribed for said infant or toddler subject.
  • 9. The method according to claim 1, wherein said infant or toddler subject is less than two years of age.
  • 10. The method according to claim 1, wherein said infant or toddler subject is not obese.
  • 11. The method of claim 10, wherein said infant or toddler subject has a normal weight.
  • 12. The method according to claim 1, wherein said plurality of parameters comprises a weight-for-length score of said infant or toddler subject.
  • 13. The method according to claim 1, wherein said plurality of parameters comprise a weight of said infant or toddler subject at age of from about 4 to about 6 months, a weight of said infant or toddler subject at age of from about 12 to about 16 months, and a weight of said infant or toddler subject at age of from about 18 to about 22 months.
  • 14. The method according to claim 1, wherein said plurality of parameters comprises a parameter pertaining to a body-mass-index of a sibling of said infant or toddler subject.
  • 15. The method according to claim 1, wherein said plurality of parameters comprises a parameter pertaining to a body-mass-index of a father of said infant or toddler subject.
  • 16. The method according to claim 1, wherein said plurality of parameters comprises a result of a hemoglobin concentration test applied to said infant or toddler subject.
  • 17. The method according to claim 1, wherein said wherein said plurality of parameters comprises a result of a mean platelet volume test applied to said infant or toddler subject.
  • 18. The method according to claim 1, wherein said plurality of parameters comprises at least 10 of the parameters listed in Table 1.1.
  • 19. A method of predicting likelihood for childhood obesity, comprising: obtaining a plurality of parameters characterizing at least one of a parent and a sibling of an unborn subject;accessing a computer readable medium storing a machine learning procedure trained for predicting likelihoods for childhood obesity;feeding said procedure with said plurality of parameters; andreceiving from said procedure an output indicative of a likelihood that said unborn subject is expected to develop childhood obesity after birth, wherein said output is related non-linearly to said parameters.
  • 20. The method according to claim 19, wherein said plurality of parameters comprises at least one parameter extracted from an electronic health record associated with said at least one of said parent and said sibling.
  • 21. The method according to claim 19, comprising presenting to a user, by a user interface, a questionnaire and a set of questionnaire controls, receiving a set of response parameters entered by said user using said questionnaire controls, wherein said plurality of parameters comprises said response parameters.
  • 22. The method according to claim 19, wherein said plurality of parameters comprises at least one parameter extracted from a body liquid test applied to said at least one of said parent and said sibling.
  • 23. The method according to claim 19, wherein said plurality of parameters comprises a parameter pertaining to a body-mass-index of said sibling.
  • 24. The method according to claim 19, wherein said plurality of parameters comprises a parameter pertaining to a body-mass-index of a father of said unborn subject.
  • 25. The method according to claim 19, wherein said plurality of parameters comprises at least 10 of the parameters listed in Table 1.2.
  • 26. A method of predicting likelihood for childhood obesity, comprising: presenting on a user interface a questionnaire and a set of questionnaire controls, and receiving from said user interface a set of response parameters entered using said questionnaire controls, wherein said set of response parameters characterizes an infant or toddler subject;accessing a computer readable medium storing a machine learning procedure trained for predicting likelihoods for childhood obesity;feeding said procedure with said set of parameters; andreceiving from said procedure an output indicative of a likelihood that said infant or toddler subject is expected to develop childhood obesity, wherein said output is related non-linearly to said parameters.
RELATED APPLICATIONS

This application claims the benefit of priority under 35 USC 119(e) of U.S. Provisional Patent Application No. 62/882,623 filed on Aug. 5, 2019, the contents of which are all incorporated by reference as if fully set forth herein in their entirety.

Provisional Applications (1)
Number Date Country
62882623 Aug 2019 US